

**COMPARATIVE STUDY OF AGE AND SEX AS RISK FACTORS OF *HELICOBACTER
PYLORI* AMONG STUDENTS OF NASARAWA STATE UNIVERSITY, KEFFI**

BY

**SALISU SULEIMAN
NSU/PGD/MCB/0050/18/19**

PGD MICROBIOLOGY

DECEMBER, 2019

**COMPARATIVE STUDY OF AGE AND SEX AS RISK FACTORS OF
HELICOBACTER PYLORI AMONG STUDENTS OF NASARAWA STATE
UNIVERSITY, KEFFI**

BY

SALISU SULEIMAN

NSU/PGD/MCB/0050/18/19


**A PROJECT SUBMITTED TO THE SCHOOL OF POST GRADUATE
STUDIES, NASARAWA STATE UNIVERSITY KEFFI, IN PARTIAL
FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF POST
GRADUATE DIPLOMA IN MICROBIOLOGY**

**DEPARTMENT OF MICROBIOLOGY
FACULTY OF NATURAL AND APPLIED SCIENCES
NASARAWA STATE UNIVERSITY, KEFFI - NIGERIA**

DECEMBER, 2019

DECLARATION

I here declare that this project has been written by me and it is a report of my research work. It has not been presented in any previous application for degree. All quotations are indicated and sources of information specifically acknowledged by means of references.



Salisu Suleiman
NSU/PGD/MCB/0050/18/19

01-03-21
Date

CERTIFICATION


This is to certify that this project titled "Comparative Study of the Prevalence and Sex as Risk Factors of *Helicobacter pylori* among Students of Nasarawa State University, Keffi" meets the regulations governing the award of Postgraduate Diploma in Microbiology, of the School of Postgraduate Studies, Nasarawa State University, Keffi and is approved for its contribution to knowledge.



Dr. A. I. Akyala
Chairman Supervisory Committee

04/02/2022


Date



Dr. D. Ishaleku
Internal Examiner

1/3/2021

Date



Dr. D. Ishaleku
Head of Department

1/3/2021


Date



Dr. Bashir Abdulkadir
External Examiner

05/03/2020


Date



Prof. U. M. Gurku
Dean of Faculty

05/03/2020

Date



Prof. J. M. Ayuba
Dean, School of Postgraduate Studies

1/3/21

Date

DEDICATION

I dedicate this research project to my master, the key of all openings who emerged as a unique treasure of the truth and for that emerged as a divine distributor and the source of all things. Prophet Muhammad may the peace and blessings of Allah be upon him, his household and sublime companions.

ACKNOWLEDGEMENT

All thanks, glory and total submission are due to Allah who in his infinite mercy has seen me through my studies and has made this project a success. May his peace and mercy be upon his noble Prophet Muhammad (PBUH).

I will like to first and foremost say a big thank you to my supervisor (an exceptional mentor) Dr A. I. Akyala for his valuable time, patience and professional advice which led to the success of this work. May the good Lord take you to greater heights.

My appreciation goes to my lecturers Prof. Smart O. Obiekezie, Prof Y.B. Ngwai, Prof. Umeh, my Head of Department, Dr David Ishaleku, Dr J.A. Owuna, Dr N. Istifanus, Mr. Moses Adoga and most of all my Course mates and the entire staff of the department of microbiology for putting heads together to make sure we are there.

My profound gratitude goes to my beloved Mother and father for their love, support and understanding during the course of this program. My siblings for always supporting me and asking me not to give up. May the Almighty Allah bless you all.

And to my partner and friend Mr. Angba Amos, Muktar whom we work tirelessly to see that this project work becomes a success.

TABLE OF CONTENT

Cover page	-	-	-	-	-	-	-	-	-	i
Title page	-	-	-	-	-	-	-	-	-	ii
Declaration	-	-	-	-	-	-	-	-	-	iii
Certification	-	-	-	-	-	-	-	-	-	iv
Dedication	-	-	-	-	-	-	-	-	-	v
Acknowledgement	-	-	-	-	-	-	-	-	-	vi
Table of contents	-	-	-	-	-	-	-	-	-	vii
List of Tables	-	-	-	-	-	-	-	-	-	x
Abstract	-	-	-	-	-	-	-	-	-	xi

CHAPTER ONE

INTRODUCTION

1.1	Background to the Study	-	-	-	-	-	-	-	1
1.2	Statement of the Problem	-	-	-	-	-	-	-	3
1.3	Justification	-	-	-	-	-	-	-	3
1.4	Aims of the Study	-	-	-	-	-	-	-	4
1.5	Objectives	-	-	-	-	-	-	-	4
1.6	Research Hypothesis	-	-	-	-	-	-	-	4

CHAPTER TWO

LITERATURE REVIEW

2.1	Epidemiology of <i>Helicobacter pylori</i>	-	-	-	-	-	-	5
-----	--	---	---	---	---	---	---	---

2.1.1 Prevalence and Geographical Distribution	-	-	-	-	-	-	-	5
2.1.2 Risk Factors for <i>Helicobacter pylori</i> Infection	-	-	-	-	-	-	-	9
2.1.3 Transmission	-	-	-	-	-	-	-	12
2.2 Microbiological Characteristics	-	-	-	-	-	-	-	13
2.2.1 Morphology	-	-	-	-	-	-	-	13
2.2.2 Genome, plasmids, and strain diversity	-	-	-	-	-	-	-	13
2.3 Virulence Factor of <i>Helicobacter pylori</i>	-	-	-	-	-	-	-	14
2.3.1 CagPAI	-	-	-	-	-	-	-	15
2.4 Pathophysiology of <i>Helicobacter pylori</i>	-	-	-	-	-	-	-	17
2.5 Clinical Aspects of <i>H. pylori</i> -Associated Diseases	-	-	-	-	-	-	-	18
2.5.1 Association with Particular Diseases	-	-	-	-	-	-	-	18
2.5.2 Disease Types	-	-	-	-	-	-	-	19
2.5.3 Acute and chronic gastritis	-	-	-	-	-	-	-	19
2.5.4 Acute Gastritis	-	-	-	-	-	-	-	21
2.5.5 Chronic gastritis	-	-	-	-	-	-	-	22
2.5.6 Peptic Ulcer Disease	-	-	-	-	-	-	-	25
2.5.7 Association with <i>H. pylori</i>	-	-	-	-	-	-	-	25
2.6 Diagnosis	-	-	-	-	-	-	-	26
2.6.1 Methods Requiring Endoscopy	-	-	-	-	-	-	-	27

2.6.2 Culture	-	-	-	-	-	-	-	-	27
2.6.2 Histologic assessment	-	-	-	-	-	-	-	-	28

CHAPTER THREE

METHODOLOGY

3.0 Methodology	-	-	-	-	-	-	-	-	30
3.1 Study Location	-	-	-	-	-	-	-	-	30
3.2 Study Population	-	-	-	-	-	-	-	-	30
3.3Data Collection	-	-	-	-	-	-	-	-	30
3.4Statistical Analysis	-	-	-	-	-	-	-	-	31
3.5 Diagnostic tests	-	-	-	-	-	-	-	-	31

CHAPTER FOUR

RESULT AND DATA PRESENTATION

4.1	Result	-	-	-	-	-	-	-	-	33
4.2	Data Analysis	-	-	-	-	-	-	-	-	34
4.3	Discussion of Findings	-	-	-	-	-	-	-	-	38

CHAPTER FIVE

SUMMARY, CONCLUSION AND RECOMMENDATIONS

5.1	Summary	-	-	-	-	-	-	-	-	41
5.2	Conclusion	-	-	-	-	-	-	-	-	41
5.3	Recommendations	-	-	-	-	-	-	-	-	42
	References	-	-	-	-	-	-	-	-	43

LIST OF TABLES

Table 1: Seroprevalence of <i>Helicobacter pylori</i> Infection amongst Students of Nasarawa State University, Keffi in Relation to Age	36
Table 2: Seroprevalence of <i>Helicobacter pylori</i> Infection amongst Students of Nasarawa State University, Keffi in Relation to Gender	36
Table 3: Seroprevalence of <i>Helicobacter pylori</i> Infection amongst Students of Nasarawa State University, Keffi in Relation to Occupation	38
Table 4: Past and Current status of Peptic Ulcer due to <i>Helicobacter pylori</i> Infection amongst Students of Nasarawa State University, Keffi	39

ABSTRACT

A study to ascertain the age and gender determinants of *Helicobacter Pylori* infection amongst students of Nasarawa State University Keffi was conducted. A total of eighty four (84) students were selected at random and blood samples were collected using the vene puncture technique and screened for the presence of *Helicobacter Pylori* using Rapid Diagnostic test strip of the 84 samples examined 46 were positive which gives an overall prevalence of 54.8%. In relation to age He highest prevalence was regarded amongst those aged 21-40 years, while the lowest prevalence was recorded within the age bracket 41 years and above (40.0%). However, there is no statistically significant association with age at $P=0.2522$. In relation to gender determinant the males had the highest sero-positivity of the infection (59.4%) than the females with a point prevalence of 51.1%. Although there exist a statistically significant association for this parameter at $P=0.0146$. Consequently there is the need for the students to continuously monitor their status in order to effectively manage the disease, mean while, individuals with cases of Peptic Ulcer should desist from consuming spicy and sour foods as they have been shown to aggravate the condition.

CHAPTER ONE

INTRODUCTION

1.1 Background to the Study

Helicobacter pylori infection is a global public health problem, affecting over 50% of the population worldwide including Africa and Asia; the two continents contributing two-third of the world's disease burden (Eshraghian, 2014).

Helicobacter pylori is motile, Gram-negative, microaerophilic bacteria. Barry Marshall and Robin Warren who isolated and identified *Helicobacter pylori* from the human stomach also drew attention to the association of *Helicobacter pylori* with gastritis; and much evidence showed that *Helicobacter pylori* causes peptic ulcers, and is also involved in the development of gastric mucosa-associated lymphoid tissue lymphoma (Morris, *et al*, Forman, *et al.*, 1990).

Infections are thought to occur early in life (during childhood) and the infection implicates several medical conditions including chronic gastritis, gastric cancer, gastric adenocarcinoma, mucosa-associated lymphoid tissue (MALT), lymphoma, and peptic ulcer disease (Plummer, *et al*, 2015). Infected individuals present with gastric reflux, abdominal pain, intestinal bleeding, occasional fevers, and loss of weight which if not treated can result in gastric ulceration and perforation (Bordin, *et al*, 2018). The incidence and prevalence rates of childhood infection with *Helicobacter pylori* vary greatly (Mohammed *et al*, 1996).

Infection with this bacterium has also been established as the etiologic factor in the development of gastric cancer, thus, *H. pylori* was designated a Class 1 carcinogen by the WHO (Alvarado-Esquivel, 2013).

Studies from many African countries reported similar prevalence rates of 91.7% in Egypt (El Dine, *et al*, 2008) 97% in Gambia (Secka *et al.*, 2011) and 75.4% in Ghana (Baako and Darko, 1996). Similarly, in Asia, prevalence rates of 92% have been reported in Bangladesh (Ahmad *et al*, 1997) and 62% prevalence was found in Chinese (Shi *et al.*, 2008).

Studies from Nigeria by Bashir and Ali (Bashir and Ali, 2009) in Kano reported an *Helicobacter pylori* prevalence of 81%, Malu *et al.* (2000) in Jos, found a prevalence of 87%, while Aboderin *et al.*, (2007) reported 73% in South-West.

Screening, treatment, and prevention of *H. pylori* colonization can reduce the incidence of gastric cancer (Ferlay, *et al.*, 2008). Other interventions that may yield a similar effect, although of smaller magnitude, include promotion of a healthy lifestyle including dietary measures, nonsmoking, low alcohol intake, and sufficient physical activity. Furthermore, increasing evidence suggests that host factors, including genetic makeup, are also important determinants for carcinogenesis in *H. pylori* infection (Malaty, *et al.*, 1994).

Studies have shown that low socio-economy is a major risk factor in *H. pylori* acquisition (Tsai *et al.*, 2005). Allaker *et al.* (2002) noted that transmission of *H. pylori* is largely by the oral–oral or fecal–oral routes. This may have been encouraged by poor environmental sanitation, crowding, and fecal contamination of water source used for irrigation of vegetables in farms or domestic use. Jemikajah and Okogun (2014) and Etukudo *et al.* (2012) in separate studies showed that sourcing water from well and borehole confers a higher risk of *H. pylori* infection than pipe-borne water. Studies also by Bateson (1993) in Glasgow and Ogihara *et al.* (2000) in Jiangsu showed that there is increased prevalence of *H. pylori* in subjects who smoked cigarettes than in those who never smoked.

1.2 Statement of the Problem

Emotional stress and psychological factors are frequently identified as important contributors to PUD.(Peters M. N, 1983). Since the mid-20th century, stress has been considered as the main cause of PUD.(Alp M. H, et'al 1970).Several studies suggested that psychological stress may play a role in the onset and course of PUD.(Jones M. P. 2006). Studies have also shown that subjects with anxiety disorders (Rogers M. P, eta'al 1994) personality disorders.(Schuster eta'al, 2010). and panic disorders(Godwin R. D, et'al,2006). are more likely to have had PUD. Individuals with neuroticism.(Cox B. J, et'al, 2006) or with a history of childhood abuse.(Fuller-Thomson E, et'al 2011). are also more likely to have PUD. The detrimental effect of stress on PUD was shown in a Japanese study that demonstrated a rise in bleeding gastric ulcers in elderly people after a catastrophic earthquake in Japan.(Aoyama N, et'al 1998).

1.4 Justification

Studies have shown that low socio-economy is a major risk factor in *H. pylori* acquisition (Tsai *et al.*, 2005). Allaker *et al.* (2002) noted that transmission of *H. pylori* is largely by the oral–oral or fecal–oral routes. This may have been encouraged by poor environmental sanitation, crowding, and fecal contamination of water source used for irrigation of vegetables in farms or domestic use. Jemikajah and Okogun (2014) and Etukudo *et al.* (2012) in separate studies showed that sourcing water from well and borehole confers a higher risk of *H. pylori* infection than pipe-borne water. Studies also by Bateson (1993) in Glasgow and Ogihara *et al.* (2000) in Jiangsu showed that there is increased prevalence of *H. pylori* in subjects who smoked cigarettes than in those who never smoked.

1.5 Aims of the Study

Comparative study of age and sex as risk factors of *Helicobacter Pylori* among students of Nasarawa State University, Keffi

1.6 Objectives

The objectives of this study include:

- i. To determine the presence of fecal occult blood in stool of peptic ulcer patient.
- ii. To provide recommendation on the management of peptic ulcer patient thereby providing health advocacy

1.7 RESEARCH HYPOTHESIS

H_1 : There is a strong association between the risk factors to be studied and increased prevalence of *H. pylori* infection

H_0 : There is no strong association between the risk factors to be studied and increased prevalence of *H. pylori* infection

H_1 : Decision rule: Accept H_1 if $P < 0.05$ statistical level of significance otherwise reject.

CHAPTER TWO

LITERATURE REVIEW

2.1 Epidemiology of *Helicobacter pylori*

2.1.1 Prevalence and Geographical Distribution

The prevalence of *H. pylori* shows large geographical variations. In various developing countries, more than 80% of the population is *H. pylori* positive, even at young ages (Perez-Perez *et al.*, 2004). The prevalence of *H. pylori* in industrialized countries generally remains under 40% and is considerably lower in children and adolescents than in adults and elderly people (Pounder *et al.*, 1995). Within geographical areas, the prevalence of *H. pylori* inversely correlates with socioeconomic status, in particular in relation to living conditions during childhood (Malaty and Graham 1994.). In Western countries, the prevalence of this bacterium is often considerably higher among first- and second-generation immigrants from the developing world (Perez-Perez *et al.*, 2005) (Tsai *et al.*, 2005). While the prevalence of *H. pylori* infection in developing countries remains relatively constant, it is rapidly declining in the industrialized world (Genta, 2002). The latter is thought to be caused by the reduced chances of childhood infection due to improved hygiene and sanitation and the active elimination of carriership via antimicrobial treatment. In developing countries, *H. pylori* infection rates rise rapidly in the first years of life and remain constantly high thereafter, indicating that *H. pylori* is acquired early in childhood (Fiedorek *et al.*, 1991).

In Europe, the prevalence of *H. pylori* seems to be lower in Northern countries than in Southern and Eastern countries. In the Netherlands, a randomly selected sample of 1550 blood donors from four different regions was tested for the presence of antibodies against *H. pylori* and the

CagA antigen (van Blankenstein *et al.*, 2013). In Eusebi *et al.*, (2014) study, only native Dutch subjects were evaluated excluding non-European immigrants. Eusebi *et al.*, (2014) reported a 32% prevalence of *H. pylori* infection, with 28% of *H. pylori* positive subjects carrying a CagA-positive strain. The seroprevalence of *H. pylori* declined from 48% in subjects born between 1935 and 1946 to 16% in those born between 1977 and 1987, as a likely consequence of a birth cohort effect. Also the proportion of CagA-positive subjects decreased from 38% to 14% in the same age cohorts. These data would suggest that a further reduction of *H. pylori* prevalence in the Netherlands over the coming decades could be expected. Additionally, from the Netherlands, a population based prospective study of a cohort of more than 6500 pregnant women was published (den Hollander *et al.*, 2013;).

Study found that the prevalence of *H. pylori* in Dutch women was 24%. The most important finding was that the prevalence of *H. pylori* was much higher in non-Dutch women with 64% of them being *H. pylori* seropositive. Moreover, in the latter group, infected subjects born abroad (first-generation immigrants) had a higher risk of *H. pylori* infection than second-generation immigrants. Thus, ethnicity was a strong predictor for *H. pylori* in this study. In contrast with northern European countries, a higher prevalence of *H. pylori* was reported in Portugal, where the prevalence of infection was 84.2%, with 61.7% of strains also positive for CagA (Bastos, *et al.*, 2013). A second evaluation, based on a proportion of included subjects, defined an incidence rate of infection of 3.6/100 person-years, confirming that Portuguese rates of *H. pylori* infection remain among the highest in Europe. Similar high values were reported in Eastern Europe. In Turkey, in a population-based cross-sectional survey, more than 4600 subjects were tested across the country, resulting in a weighted overall prevalence of infection of 82.5% (Ozaydin *et al.*, 2013). Interestingly, the prevalence was lowest among individuals living in the southern part of

the country who usually have a citrus fruit rich diet, as this is the major citrus fruit-growing area. Indeed, vitamin C is effective in the prevention of most infections; thus, the authors suggested that it might also play a role in *H. pylori* infection. In North America, the prevalence of *H. pylori* seems to be similar to northern Europe. Further evidence was provided by a Canadian study where the presence of *H. pylori* infection was evaluated in 203 aboriginal patients with dyspepsia referred for gastroscopy. *H. pylori* infection was reported by histology in 37.9% of patients (Sethi *et al.*, 2013). To the contrary, a study from Mexico (Alvarado-Esquivel, 2013) confirmed the previously reported (Porras, *et al.* 2013) high prevalence of *H. pylori* infection in Latin America. A seroprevalence of 52.2% was reported among 343 pregnant women living in rural areas in Mexico. In Asia, the studies published over the last year showed high prevalence rates of *H. pylori* infection ranging from 54% to 76% (Lim , *et al.*, 2013; Zhu *et al.*, 2014; Sodhi, *et al.*, 2013; Adlekha *et al.*, 2013; Benberin *et al.*, 2013; Vilaichone *et al.*, 2013; Dorji *et al.*, 2014) Only one study carried out on healthy individuals in Saudi Arabia showed a low prevalence of infection of about 28% (Hanafi and Mohamed 2013).

In Korea, in a large cross-sectional nationwide multicenter study, more than 10,000 asymptomatic subjects without a history of *H. pylori* eradication were enrolled (Lim, *et al.*, 2013). The seroprevalence of infection was 54.4%. However, this estimate was lower than that reported in the same country by two similar surveys performed in 1998 (Kim *et al.* 2001) and 2005 (Yim, *et al.*, 2007), where the prevalence of *H. pylori* was 66.9% and 59.6%, respectively. This decrease was significant across all age groups and in most areas of the country. In China, a survey of *H. pylori* infection was carried out on a sample of the general population from areas with high incidence of gastric cancer (Zhu *et al.*, 2014). A total of 5417 healthy individuals aged between 30 and 69 years were tested with the 13C-urea breath test. The prevalence of *H. pylori*

underwent gastroscopy with gastric biopsies, were evaluated for the presence of *H. pylori* infection (Yu *et al.*, 2014). The histologic examination of gastric biopsies showed a 32.1% prevalence of *H. pylori* infection. A higher rate of infection in children was reported in Iran, where Ghasemi-Kebria *et al.* found a seroprevalence of 50.5%, with 61.7% of children also positive for CagA (Ghasemi-Kebria *et al.*, 2013).

2.1.2 Risk Factors for *Helicobacter pylori* Infection

Several studies investigated putative risk factors for *H. pylori* infection. Gender and age do not seem to be associated with an increased risk of infection. Indeed, most studies reported no significant difference of *H. pylori* infection between men and women, both in adults (van Blankenstein *et al.*, 2013; Adlekha *et al.*, 2013; Vilaichone *et al.*, 2013; Hanafi and Mohamed 2013; Benajah *et al.*, 2013; Mathewos *et al.*, 2013) and in children (Mana *et al.*, 2013; Bastos *et al.*, 2013; Ghasemi-Kebria *et al.*, 2013). No significant association was found between infection and age in the adult population (den Hollander *et al.*, 2013; Alvarado-Esquivel 2013; Adlekha *et al.*, 2013; Benberin *et al.*, 2013; Dorji *et al.*, 2014; Hanafi and Mohamed 2013; Mana *et al.*, 2013). The age-specific gradient in *H. pylori* prevalence reported by some studies seems to be related to a birth cohort effect (van Blankenstein *et al.*, 2013, Lim, *et al.*, 2013; Benajah *et al.*, 2013, Mathewos *et al.*, 2013; Yu *et al.*, 2014).

Several socioeconomic factors have been associated with *H. pylori* infection. In particular, subjects with a low socioeconomic status (den Hollander *et al.*, 2013; Hanafi and Mohamed 2013), measured also as a low family income (Lim *et al.*, 2013; Zhu *et al.*, 2014), had a higher likelihood of carrying *H. pylori* infection. Furthermore, an inverse association between educational level and *H. pylori* infection was found in the majority of the studies (den Hollander *et al.*, 2013; Ozaydin *et al.*, 2013; Benajah *et al.*, 2013); indeed, except for two cases (Alvarado-

Esquivel, 2013; Zhu *et al.*, 2014;), individuals with lower educational levels had a higher risk than those with a higher education. The same association concerning the parents' education was also found in studies on children (Mana *et al.*, 2013; Bastos *et al.*, 2013).

Moreover, several factors related to residence have been found to be associated with the infection. Indeed, living in a rural area (Lim *et al.*, 2013; Vilaichone *et al.*, 2013; Hanafi and Mohamed, 2013), in crowded homes (Dorji *et al.*, 2014; Hanafi and Mohamed, 2013; Bastos *et al.*, 2013), and having contaminated sources of drinking water (Ozaydin *et al.*, 2013) were risk factors for *H. pylori* infection. Among the main lifestyle habits, smoking and alcohol consumption showed discordant results: Although in most studies, there was no significant association with *H. pylori* infection (den Hollander *et al.*, 2013; Zhu *et al.*, 2014; Benajah *et al.*, 2013), some authors reported that regular smokers (Ozaydin *et al.*, 2013; Hanafi and Mohamed, 2013) and drinkers (Hanafi and Mohamed, 2013) were at higher risk. In contrast, in one study, regular alcohol drinking was a protective factor for *H. pylori* infection (Ozaydin *et al.*, 2013).

Table 1: Prevalence of *Helicobacter pylori* infection in adults reported by studies published in 2013

Country	Setting	Number	Diagnostic method	Prevalence of <i>Helicobacter pylori</i> (%)
Western Europe				
The Netherlands	Blood donors	1550	Serology	31.7
The Netherlands	Pregnant women	6837	Serology	46
Portugal	General population	2067	Serology	84.2
Eastern Europe				
Cyprus	Patients with dyspepsia	103	PCR	39.8
Turkey	General population	4622	UBT	82.5
America				
Canada	Aboriginal population	203	Histology	37.9
Mexico	Pregnant women	343	Serology	52.2
Asia				
Saudi Arabia	Healthy individuals	456	Serology	28.3
Korea	Routine health check-up	10796	Serology	54.4
India	Patients with dyspepsia	2000	Histology	58
			RUT	
India	Patients with dyspepsia	530	Histology	62
			Urease test	
China	Healthy individuals	5417	UBT	63.4
Bhutan	Volunteers	372	Histology	73.4
			RUT	
			Culture	
			Serology	
Bhutan	Patients with dyspepsia	241	Serology	86
Kazakhstan	Asymptomatic and patients with dyspepsia	835	Serology	76.5
Africa				
Liberia [Selected population	1388	Serology	65.7
Morocco	Patients with dyspepsia	429	Histology	75.5
			RUT	
			Culture	
Nigeria	Patients with dyspepsia	125	Serology	93.6
			Histology	80

UBT, urea breath test; RUT, rapid urease test.

Table 2 Prevalence of *Helicobacter pylori* infection in children reported by studies published in 2013

Country	Age of included subjects (years)	Number	Diagnostic method	Prevalence of <i>Helicobacter pylori</i> (%)
Western Europe				
Belgium	12-25	516	UBT	11
Portugal	13	1312	Serology	66.2
America				
Brazil	2-19	129	Histology	41.1
			RUT	
			Culture	
Asia				
China	1-18	1634	Histology	32.1
			RUT	
Iran	1-15	194	Serology	50.5

UBT, urea breath test; RUT, rapid urease test.

Source : Special Issue: The Year in Helicobacter 2014, Volume19, Issues1.

Epidemiology of *Helicobacter pylori* Infection

2.1.3 Transmission

There appears to be no substantial reservoir of *H. pylori* aside from the human stomach. Other animals harbor organisms that resemble *H. pylori*, but with the exception of nonhuman primates (Dubois *et al.*, 1994) and, under particular circumstances, perhaps cats (Fox *et al.*, 1995), none harbor *H. pylori*. Thus, the major question of transmission is how *H. pylori* travel from the stomach of one person to that of another. Three routes have been described. The first and least common is iatrogenic, in which tubes, endoscopes, or specimens in contact with the gastric mucosa from one person are introduced to another person (Akamatsu *et al.*, 1996). Improved disinfection of endoscopes has reduced the incidence of transmission (Kato *et al.*, 1993) (Tytgat, 1995). Interestingly, endoscopists, especially those who did not wear gloves during procedures, were at increased risk of becoming infected (Mitchell *et al.*, 1989). Occupationally acquired infections also have been reported (Sobala *et al.*, 1991); although there does not appear to be any special risk associated with handling this organism, laboratory workers should use universal precautions when handling clinical specimens and should remember that *H. pylori* strains are human pathogens. Fecal-oral transmission is perhaps most important. Although *H. pylori* has been isolated from the feces of young children infected with the organism (Thomas *et al.*, 1992), fecal isolation is not common; this could indicate that shedding is intermittent. Fecally contaminated water may be a source of infection (Klien *et al.*, 1991), but the organism has not been isolated from water. Food-borne transmission has not been substantiated.

2.2 MICROBIOLOGICAL CHARACTERISTICS

2.2.1 Morphology

Helicobacter pylori is a helix-shaped (classified as a curved rod, not spirochaete) Gram-negative bacterium about 3 μm long with a diameter of about 0.5 μm . *H. pylori* can be demonstrated in tissue by Gram stain, Giemsa stain, haematoxylin–eosin stain, Warthin–Starry silver stain, acridine orange stain, and phase-contrast microscopy. It is capable of forming biofilms (Stark *et al.*, 1999) and can convert from spiral to a possibly viable but nonculturable coccoid form. (Chan *et al.*, 1994). *Helicobacter pylori* has four to six flagella at the same location; all gastric and enterohepatic *Helicobacter* species are highly motile owing to flagella. (Josenhans *et al.*, 2000) The characteristic sheathed flagellar filaments of *Helicobacter* are composed of two copolymerized flagellins, FlaA and FlaB (Rust *et al.*, 2008).

2.2.2 Genome, plasmids, and strain diversity.

The size of the two sequenced *H. pylori* genomes is approximately 1.7 Mbp, with a GC content of 35 to 40%. The *H. pylori* strain 26695 genome includes 1,587 genes, whereas the genome of strain J99 includes only 1,491 genes (Boneca *et al.*, 2003). Both genomes contain two copies of the 16S, 23S, and 5S rRNA genes. Many strains carry one or more cryptic plasmids, which do not seem to carry antibiotic resistance genes or virulence genes (Heuermann and Haas, 1995). The existence of *H. pylori*-infecting bacteriophages has been reported, but detailed characterization is lacking (Schmid *et al.*, 1990). In contrast to other bacterial pathogens that are highly clonal (such as *Shigella dysenteriae* and *Mycobacterium tuberculosis*), *H. pylori* is genetically heterogeneous, suggesting a lack of clonality. This results in every *H. pylori*-positive subject carrying a distinct strain (Kansau *et al.*, 1996), although differences within relatives may

be small. The genetic heterogeneity is possibly an adaptation of *H. pylori* to the gastric conditions of its host, as well as to the distinct patterns of the host-mediated immune response to *H. pylori* infection (Kuipers, *et al.*, 2000). Genetic heterogeneity is thought to occur via several methods of DNA rearrangement and the introduction and deletion of foreign sequences (Achtman and Suerbaum 2000; Falush *et al.*, 2003; Suerbaum and Achtman 2004). The latter usually have an aberrant GC content and often carry genes involved in virulence. A striking example of this in *H. pylori* is the *cag* PAI, but other plasticity regions have also been suggested to play a role in the pathogenesis of *H. pylori* infection (Jonge *et al.*, 2004; Lehours, *et al.*, 2004; Occhialini *et al.*, 2000; Santos *et al.*, 2003). Diversity is also seen at the nucleotide level via several mechanisms, including transcriptional and translational phase variation and mutation (Achtman and Suerbaum 2000; Falush *et al.*, 2001). Phase variation often occurs via reversible slipped-strand mispairing in homopolymeric G or C tracts, which causes a shift in translation of the affected gene, thus resulting in phase variation via a single mutation. This leads to a reversible phenotypic diversity with only minor genetic variation. Several virulence genes, such as the *sabA*, *sabB*, *hopZ*, and *oipA* outer membrane protein-encoding genes, display such phenotypic variation, as do lipopolysaccharide (LPS) biosynthetic enzymes (Mahdavi *et al.*, 2002).

2.3 Virulence Factor of *Helicobacter pylori*

Although infection with *H. pylori* almost always results in chronic active gastritis, most infected patients develop no other complications and are free of any obvious clinical symptoms of this infection (Blaser and Atherton , 2004.). This led to the notion that some strains may be more virulent than others. Early investigations of the differential pathogenic properties of *H. pylori* strains indicated that this increased pathogenicity correlated with the ability of these more

virulent strains to induce morphological changes, vacuolization, and successive degeneration of in vitro-cultured cells (Leunk, *et al.*, 1988). This activity was then linked to the presence of a protein with a molecular mass of approximately 140 kDa that was named CagA (for “cytotoxin associated gene A”).

2.3.1 *CagPAI*

CagPAI is a 40kb region of chromosomal DNA encoding approximately 31 genes that forms a type IV secretion system and can be divided into two regions, *cag I* and *cag II*, according to a novel insertion sequence (Censini *et al.*, 1996). This secretion system forms a pilus that delivers *CagA*, an oncoprotein, into the cytosol of gastric epithelial cells through a rigid needle structure covered by CagY, a VirB10-homologous protein, and CagT, a VirB7-homologous protein, at the base (Covacci *et al.*, 2000; Rohde *et al.*, 2003; Backert and Selbach, 2008).

Upon delivery into host cells by the *cag* secretion system, the product of the terminal gene in the island, *CagA*, undergoes Src-dependent tyrosine phosphorylation and activates an eukaryotic phosphatase (SHP-2), leading to dephosphorylation of host cell proteins and cellular morphological changes (Odenbreit *et al.*, 2000; Higashi *et al.*, 2002). *CagA* has also been shown to dysregulate b-catenin signaling (Franco *et al.*, 2005; Murata-Kamiya *et al.*, 2007) and apical-junctional complexes, (Amieva, 2003) events that have been linked to increased cell motility and oncogenic transformation in a variety of models (Suzuki *et al.*, 2005; Franco *et al.*, 2008). In addition, some studies have reported that *cagPAI* appears to be involved in the induction of gastric interleukin-8 (IL-8) production, a potent neutrophil-activating chemokine (Brandt *et al.*, 2005).

Consequently, the presence of *cagA* gene has been associated with higher grades of inflammation, which may lead to the development of the most severe gastrointestinal diseases, such as peptic ulcer disease (Figueiredo *et al.*, 2001) and GC (Wang, *et al.* 2007; Roesler *et al.*, 2011).

In Western countries, it has been reported that individuals infected with *cagA*-positive strains of *H. pylori* are at a higher risk of peptic ulcer disease or GC than those infected with *cagA*-negative strains (Yamaoka 2008; van Doorn , *et al.*, 1998).

However, in East Asia, most strains of *H. pylori* have the *cagA* gene irrespective of the disease (Yamaoka *et al.*, 1999).

Furthermore, *cagA* is a polymorphic gene that presents different numbers of repeated sequences located in its 3' region. Each repeated region of CagA protein contains Glu-Pro-IleTyr-Ala (EPIYA) motifs, including a tyrosine phosphorylation site (Hatakeyama, 2004).

According to the sequences flanking the EPIYA motifs, four distinct EPIYA segments, EPIYA-A, EPIYA-B, EPIYA-C, and EPIYA-D, each of which contains a single EPIYA motif, have been identified in the EPIYA-repeat region. The EPIYA-repeat region of *CagA* from Western *H. pylori* isolates is in arrangement of EPIYA-A, EPIYA-B, and EPIYA-C segments (A-B-C-type *CagA*). The EPIYA-C segment variably multiplies (mostly one to three times) in tandem among different Western *CagA* species. *CagA* from East Asian *H. pylori* isolates also possesses EPIYA-A and EPIYA-B segments, but not the repeatable EPIYA-C segment. Instead, it has a distinct EPIYA-containing segment (it is the EPIYA-D segment), which is unique to East Asian *CagA*. Accordingly, the EPIYA-repeat region of East Asian *CagA* is in an arrangement of EPIYA-A, EPIYA-B, and EPIYA-D segments (A-B-D-type *CagA*) (Higashi, *et al.*, 2002;

Hatakeyama, 2009). Analysis using a series of EPIYA mutants of CagA revealed that SHP-2 specifically binds to the tyrosinephosphorylated EPIYA-C or EPIYA-D segment. The sequence flanking the tyrosine phosphorylation site of EPIYA-D segment perfectly matches the consensus high affinity binding sequence for the SH2 domains of SHP-2, whereas that flanking the tyrosine phosphorylation site of the EPIYA-C segment differs from the consensus sequence by a single amino acid at the pY+5 position. As a result, East Asian CagA, which contains the EPIYA-D segment, exhibits stronger SHP-2 binding than does Western CagA, which contains the EPIYA-C segment. Within Western CagA species, those having a greater number of EPIYA-C segments exhibit stronger activity to interact with SHP-2 and are more closely associated with precancerous lesions and GC (Higashi, *et al* 2002; Hatakeyama, 2009).

As regard to the function of the repeated regions, initial demonstrations suggest that *H. pylori* strains that have a larger number of EPIYA segments in their regions are less resistant to gastric acid (Yamaoka *et al.*, 1999). This finding seems to indicate that *H. pylori* strains containing many EPIYA segments can survive only in the presence of advanced atrophic gastritis, in which gastric acid secretion is low (Yamaoka, 2011).

2.4 Pathophysiology of *Helicobacter pylori*

In order to avoid the acidic environment of the interior of the stomach (lumen), *H. pylori* uses its flagella to burrow into the mucus lining of the stomach to reach the epithelial cells underneath, where it is less acidic. (Amieva and El-Omar, 2008). *H. pylori* is able to sense the pH gradient in the mucus and move towards the less acidic region (chemotaxis). This also keeps the bacteria from being swept away into the lumen with the bacteria's mucus environment, which is constantly moving from its site of creation at the epithelium to its dissolution at the lumen interface. (Schreiber *et al.*, 2004). *H. pylori* is found in the mucus, on the inner surface of the

epithelium, and occasionally inside the epithelial cells themselves (Petersen and Krogfelt 2003). It adheres to the epithelial cells by producing adhesins, which bind to lipids and carbohydrates in the epithelial cell membrane. One such adhesin, BabA, binds to the Lewis b antigen displayed on the surface of stomach epithelial cells. (Ilver *et al.*, 1998) *H. pylori* adherence via BabA is acid sensitive and can be fully reversed by increased pH. It has been proposed that BabA's acid responsiveness enables adherence while also allowing an effective escape from unfavorable environment at pH that is harmful to the organism. (Bugaytsova *et al.*, 2017). Another such adhesin, SabA, binds to increased levels of sialylLewis x antigen expressed on gastric mucosa (Mahdavi *et al.*, 2002). "In addition to using chemotaxis to avoid areas of low pH, *H. pylori* also neutralizes the acid in its environment by producing large amounts of urease, which breaks down the urea present in the stomach to carbon dioxide and ammonia. These react with the strong acids in the environment to produce a neutralized area around *H. pylori* (Mobley, *et al.*, 2001). Urease knockout mutants are incapable of colonization. In fact, urease expression is not only required for establishing initial colonization but also for maintaining chronic infection(Debowski *et al.*, 2017).

2.5 Clinical Aspects of *H. pylori*-Associated Diseases

2.5.1 Association with Particular Diseases

All *H. pylori*-infected patients develop chronic gastric inflammation (Blaser, 1990), but this condition usually is asymptomatic. This gastritis is not a disease or illness per se. Peptic ulcer disease had been considered to be idiopathic or to be due to agents such as aspirin or nonsteroidal anti-inflammatory drugs or, rarely, to Zollinger-Ellison syndrome, Crohn's disease, and several other inflammatory disorders (Peterson, 1991). The idiopathic form of peptic ulcer disease represents 60 to 95% of all cases (depending on the extent of nonsteroidal anti-

inflammatory drug use in the population); we now know that *H. pylori* is the cause of nearly all of these cases in adults (NIH Consensus Conference, 1994) and that treatment that eradicates *H. pylori* leads to cure of the ulcers. Thus, in any population, *H. pylori* causes the majority of all cases of both gastric and duodenal ulcers. Carriage of *H. pylori* also is strongly associated with the risk of development of atrophic gastritis (Blaser, 1990), which is a precursor lesion to gastric cancer. Thus, not surprisingly, *H. pylori* carriage also is associated with adenocarcinoma of the distal but not the proximal (cardia) stomach (Talley *et al.*, 1991). Infection is associated with both the intestinal and diffuse histologic types of tumors. This association is extremely important since, in total, gastric cancer is the second leading cause of cancer death in the world (Neugut, 1996).


2.5.2 Disease Types

Although gastric colonization with *H. pylori* induces histologic gastritis in all infected individuals, only a minority develop any apparent clinical signs of this colonization. It is estimated that *H. pylori*-positive patients have a 10 to 20% lifetime risk of developing ulcer disease and a 1 to 2% risk of developing distal gastric cancer (Kuipers, 1998). The risk of development of these disorders in the presence of *H. pylori* infection depends on a variety of bacterial, host, and environmental factors that mostly relate to the pattern and severity of gastritis (*Fig. 2*).

2.5.3 Acute and chronic gastritis

Colonization with *H. pylori* virtually always leads to infiltration of the gastric mucosa in both antrum and corpus with neutrophilic and mononuclear cells (*Fig. 1A*). This chronic active

gastritis is the primary condition related to *H. pylori* colonization, and other *H. pylori*-associated disorders in particular result from this chronic inflammatory process.



(1A) Gastric glands abundantly colonized with *Helicobacter pylori*, shown as dark, curved bacilli closely aligning with the mucosal surface. (1B) Endoscopic view of a gastric ulcer, with a clean base at the angulus.

Source: Clinical Microbiology Reviews July, 2006 American Society for Microbiology

2.5.4 Acute Gastritis

Data on the acute phase of infection are scarce and largely come from reports of subjects who deliberately or inadvertently ingested *H. pylori* or underwent procedures with contaminated material (Solnick, *et al.*, 1999). Recently, a human challenge model for *H. pylori* infection was introduced; it allowed controlled studies of the acute phase of infection with deliberate infection of healthy volunteers with a well-characterized laboratory strain of *H. pylori* (Graham *et al.*, 2004). Together, these reports showed that the acute phase of colonization with *H. pylori* may be associated with transient nonspecific dyspeptic symptoms, such as fullness, nausea, and vomiting, and with considerable inflammation of both the proximal and distal stomach mucosa, and pangastritis. This phase is often associated with hypochlorhydria, which can last for months. It is unclear whether this initial colonization can be followed by spontaneous clearance and resolution of gastritis and, if so, how often this occurs. Follow-up studies of young children with serology or breath tests suggested that infection may spontaneously disappear in some patients in this age group (Granstrom, *et al.*, 1997; Malaty, *et al.*, 1999. Perez-Perez, *et al.*, 2003); this has not been observed in adults other than under specific circumstances, such as development of atrophic gastritis. However, studies of homozygotic twins showed a concordance in their *H. pylori* status irrespective of whether they had grown up together or apart (Malaty, *et al.*, 1994). Such a concordance was not observed among heterozygotic twins. This suggests that some individuals are prone to *H. pylori* colonization while others may be able to prevent colonization or clear an established infection. This hypothesis is also supported by the observation that in many developing countries the level of exposure to *H. pylori* is very high (i.e., 90%) at young ages and yet some individuals never develop persistent *H. pylori* infection.




FIG. 2. Schematic representation of the factors contributing to gastric pathology and disease outcome in *H. pylori* infection.

Source: Clinical Microbiology Reviews July, 2006 American Society for Microbiology

2.5.5 Chronic gastritis

When colonization does become persistent, a close correlation exists between the level of acid secretion and the distribution of gastritis (Fig. 3). This correlation results from the counteractive effects of acid on bacterial growth versus those of bacterial growth and associated mucosal inflammation on acid secretion and regulation. This interaction is crucial in the determination of outcomes of *H. pylori* infection. In subjects with intact acid secretion, *H. pylori* in particular colonizes the gastric antrum, where few acid-secreting parietal cells are present. This colonization pattern is associated with an antrum-predominant gastritis. Histological evaluation of gastric corpus specimens in these cases reveals limited chronic inactive inflammation and low numbers of superficially colonizing *H. pylori* bacteria. Subjects in whom acid secretion is

impaired, due to whatever mechanism, have a more even distribution of bacteria in antrum and corpus, and bacteria in the corpus are in closer contact with the mucosa, leading to a corpus-predominant pangastritis (Kuipers, *et al.*, 1995). The reduction in acid secretion can be due to a loss of parietal cells as a result of atrophic gastritis, but it can also occur when acidsecretory capacity is intact but parietal cell function is inhibited by vagotomy or acid-suppressive drugs, in particular, proton pump inhibitors (PPIs) (Kuipers, *et al.*, 1995). The resulting active inflammation of the corpus mucosa further augments hypochlorhydria, paralleling the acute phase of infection, as local inflammatory factors such as cytokines, including interleukin-1 (IL-1), have a strong suppressive effect on parietal cell function. This is illustrated by various observations. Firstly, *H. pylori* corpus gastritis is often associated with hypochlorhydria, and eradication therapy leads to increased acid secretion in these subjects (El-Omar, *et al.*, 1997; Ruiz, *et al.*, 1996). Secondly, *H. pylori* corpus gastritis augments the acid-suppressive effects of PPIs (Verdu', *et al.*, 1995). As a result, *H. pylori* positive patients with gastroesophageal reflux disease (GERD) may respond somewhat faster to PPI treatment both with respect to symptom resolution and with healing of esophagitis (Holtmann, *et al.*, 1999), but this effect is minimal and largely irrelevant in daily clinical practice. This means that there is no general need to take *H. pylori* status into account when decisions on the dose of PPI treatment for GERD must be made. A third observation in support of the acid-suppressive effects of active corpus gastritis comes from more recent, important research showing that subjects with proinflammatory genotypes have a higher risk of corpus-predominant pangastritis, predisposing them to atrophic gastritis, intestinal metaplasia, and gastric cancer (El Omar, *et al.*, 2000). Although colonization with *H. pylori* is almost invariably associated with the presence of gastritis, and gastritis is mostly due to *H. pylori* colonization, other causes of gastritis include infections such as cytomegalovirus,

chronic idiopathic inflammatory and autoimmune disorders such as Crohn’s disease and pernicious anemia, and chemical damage due to alcohol abuse or nonsteroidal anti-inflammatory drug (NSAID) use.



Pattern of gastritis	Gastric histology	Duodenal histology	Acid secretion	Clinical condition
 <p>Pan-gastritis</p>	<ul style="list-style-type: none"> Chronic inflammation Atrophy Intestinal metaplasia 	<ul style="list-style-type: none"> Normal 	<ul style="list-style-type: none"> Reduced 	<ul style="list-style-type: none"> Gastric ulcer Gastric cancer
 <p>Antral-precoinant</p>	<ul style="list-style-type: none"> Chronic inflammation Polyomorph activity 	<ul style="list-style-type: none"> Gastric metaplasia Active chronic inflammation 	<ul style="list-style-type: none"> Increased 	<ul style="list-style-type: none"> Duodenal ulcer

FIG. 3. Acid secretion and the associated pattern of gastritis play an important role in disease outcome in *H. pylori* infection. The figure displays the correlations between the pattern of *H. pylori* colonization, inflammation, acid secretion, gastric and duodenal histology, and clinical outcome.

Source: Clinical Microbiology Reviews July, 2006 American Society for Microbiology

2.5.6 Peptic Ulcer Disease.

Gastric or duodenal ulcers (commonly referred to as peptic ulcers) are defined as mucosal defects with a diameter of at least 0.5 cm penetrating through the muscularis mucosa (Fig. 1B). Gastric ulcers mostly occur along the lesser curvature of the stomach, in particular, at the transition from corpus to antrum mucosa (Veldhuyzen *et al.*, 1999). Duodenal ulcers usually occur in the duodenal bulb, which is the area most exposed to gastric acid. In Western countries, duodenal ulcers are approximately fourfold more common than gastric ulcers; elsewhere, gastric ulcers are more common. Duodenal ulcers in particular occur between 20 and 50 years of age, while gastric ulcers predominantly arise in subjects over 40 years old.

2.5.7 Association with *H. pylori*

Both gastric and duodenal ulcer diseases are strongly related to *H. pylori*. In initial reports from all over the world in the first decade after the discovery of *H. pylori*, approximately 95% of duodenal ulcers and 85% of gastric ulcers occurred in the presence of *H. pylori* infection (Kuipers, *et al.*, 1995). Several cohort studies estimated that the lifetime risk for ulcer disease in *H. pylori*-positive subjects is 3 to 10 times higher than in *H. pylori*-negative subjects (Nomura, *et al.*, 1994) and that 10 to 15% of *H. pylori*-positive subjects developed ulcer disease during long-term follow-up (Cullen, *et al.*, 1993). These data came from studies in developed areas of the world. It is unknown whether *H. pylori*-positive subjects in developing countries have similar disease risks. Introduction of *H. pylori* eradication regimens completed the evidence for a causal relation between *H. pylori* and ulcer disease by showing that eradication of this bacterium strongly reduced the risk of recurrent ulcer disease (Rauws, *et al.*, 1990). This has had a major impact on the treatment and course of peptic ulcer disease in daily clinical practice. In earlier days, this disease was a chronic, recurrent disorder with high morbidity, frequently requiring

acid-suppressive maintenance therapy or surgery. Approximately 50% of patients with *H. pylori*-associated peptic ulcer disease suffered ulcer recurrence within 1 year (Rauws, *et al.*, 1990). Eradication of *H. pylori* dramatically changes the natural course of ulcer disease and almost completely prevents ulcer recurrence (268, Rauws, *et al.*, 1990; van der Hulst, *et al.*, 1997). Ulcer recurrences after *H. pylori* eradication therapy can be due to persistent or renewed *H. pylori* infection, use of NSAIDs, or idiopathic ulcer disease. Ulcer development in the presence of *H. pylori* is influenced by a variety of host and bacterial factors. Ulcers mostly occur at sites where mucosal inflammation is most severe (Veldhuyzen, *et al.*, 1999) (*Fig. 3*). In subjects with decreased acid output, this usually is the gastric transitional zone between corpus and antrum, giving rise to gastric ulcer disease. If acid production is normal to high, the most severe inflammation usually is found in the distal stomach and proximal duodenum, giving rise to juxtapyloric and duodenal ulcer disease.

2.6 DIAGNOSIS

Various tests have been developed for the detection of *H. pylori*, each with their specific advantages and disadvantages. A variety of tests are now available to diagnose *H. pylori* infection. Histological examination of gastric tissue, bacterial culture, rapid urease testing, use of DNA probes, and PCR analysis, when used to test gastric tissue, all require endoscopy; therefore they incur expense and a risk, albeit slight, of complication due to the procedure. In contrast, breath tests, serology, gastric juice PCR, and urinary excretion of [^{15}N] ammonia are noninvasive tests that do not require endoscopy. The choice of test used for diagnosis of *H. pylori* infection will depend, in most cases, on the clinical information sought and the local availability and cost of individual tests.

2.6.1 Methods Requiring Endoscopy

At endoscopy, many adults with *H. pylori*-associated gastritis have normal-appearing gastric mucosa. The distribution of *H. pylori* and the associated inflammation is often patchy. The patchy nature of infection can lead to endoscopic sampling error, resulting in false-negative biopsy, culture, and rapid urease test results. At a minimum, two biopsy specimens taken from within 5 cm of the pylorus should be obtained at endoscopy, with multiple sections being examined histologically (Sobala *et al.*, 1991). Genta and Graham (1994) however, reported a sensitivity of 100% with biopsy specimens taken from the angularis of the stomach. Two conditions observable directly by the endoscopist, antral nodularity and uncomplicated duodenal ulcer disease, are almost always associated with *H. pylori* infection (Laine *et al.*, 1995); hence, testing for *H. pylori* in these settings may not be necessary.

2.6.2 Culture

Culture of *H. pylori* has two major advantages. First, it allows antimicrobial susceptibility testing; second, isolates obtained by culture can be characterized in detail. Although the sensitivity of culture in experienced laboratories is greater than 95%, other methods for the diagnosis of *H. pylori* infection are simpler, prone to less variability, and more timely. Culture of gastric biopsy specimens typically provides the greatest yield of *H. pylori*. However, culture of gastric juice occasionally has been successful, and there are reports of successful culture from feces (Kelly Pitcher *et al.*, 1994; Thomas, *et al.*, 1992). Only the principles of culture techniques for gastric biopsies are reviewed below. Although preimmersion of biopsy forceps in formaldehyde does not appear to adversely influence the recoverability of organisms in culture (Yousfi, *et al.*, 1996), we recommend that gastric mucosal samples for culture be obtained initially (before sampling for histology or other tests). Saline is a simple acceptable short-term

(,6 h) transport medium (Han, *et al.*, 1995; Veenendaal *et al.*, 1993). If the culture is to be delayed, more complex media such as Stuart's medium or supplemented brain heart infusion broth should be used (Han, *et al.*, 1995). Media containing glycerol are suitable for long-term storage of biopsy specimens at 270°C (Han, *et al.*, 1995), or the specimens can be immediately frozen at 270°C without a fluid medium. A variety of selective and nonselective media are available commercially for culture of *H. pylori* (Hachem *et al.*, 1995). The use of multiple media may increase sensitivity. *H. pylori* requires a microaerobic environment, high humidity, and incubation at 35 to 37°C for a maximum of 7 to 10 days. Positive cultures are usually detected after 3 to 5 days of incubation. *H. pylori* is identified on the basis of colony morphology (translucent colonies varying in size from barely detectable with the naked eye to approximately 3 mm); colonies consist of gram-negative, curved (not usually helical) rods that are urease, catalase, and oxidase positive. The addition of tetrazolium salts aids in the identification of *H. pylori* colonies cultured on agar media (Queiroz, *et al.*, 1987).

2.6.2 Histologic assessment

H. pylori can be visualized at high magnification with conventional hematoxylin and eosin (H&E)- stained sections. Bacteria are located in the mucus adherent to the surface epithelium and are often found deep within the crypts. However, H&E staining may be unreliable when few bacteria are present. In addition, luminal debris on the surface of the epithelium can be mistaken for *H. pylori* in H &E stained sections. Histological identification of bacteria is facilitated by using special stains such as the Warthin-Starry and modified Giemsa stains (el-Zimaity, *et al.*, 1996; Genta and Graham, 1994). The distribution of *H. pylori* in the stomach is not uniform, nor are organisms usually found in areas of intestinal metaplasia (Genta, *et al.*, 1996). Histologic identification of bacteria with the characteristic morphology of *H. pylori* is, in part, observer

dependent. Factors that influence the ability to correctly identify *H. pylori* include bacterial density, type of stain used, and the enthusiasm and experience of the laboratorian (Laine, *et al.*, 1997; Molyneux and Harris, 1993). A sensitive staining technique consisting of a combination of H & E, Steiner silver stain, and alcian blue has been developed by Genta *et al.* (1994). This stain reportedly allows ready detection of *H. pylori* while simultaneously allowing evaluation of gastric histology, thus obviating the need for additional staining. However, the Genta stain procedure can be technically difficult, and its acceptance among gastrointestinal pathologists has not been universal (Laine, *et al.*, 1997). Selection of cases needing special staining (if not performed routinely) may be guided by the inflammatory infiltrate of the gastric biopsy specimens. In the absence of inflammation, the likelihood of *H. pylori* infection is remote, and special stains are not indicated. However, if an active inflammatory infiltrate is present and *H. pylori* is not detected, special stains may be appropriate. In fact, the presence of histologically active gastric inflammation in a patient not previously treated for *H. pylori* infection may be pathognomonic for *H. pylori* infection (Cutler, *et al.*, 1995.). In summary, sole reliance on H&E staining when few *H. pylori* organisms are identified or when *H. pylori* is not detected in the presence of significant inflammation may be imprudent. Immunohistochemical staining techniques also have been developed to detect *H. pylori* (Ashton-Key *et al.*, 1996).

CHAPTER THREE

METHODOLOGY

3.0 METHODOLOGY

3.1 Study Location

Keffi is a city found in Nasarawa State, Nigeria. It is located at 8.85° latitude and 7.87° longitudes and it is situated at elevation 321 meters above the sea level. Keffi has a population of about 85,911 making it the second biggest city in Nasarawa State. South Atlantic Petroleum Medical Center is located within the environs of Nasarawa State University, keffi where must of the University community members seek medical care.

3.2 Study Population

The study population cover the University community members who are peptic ulcer positive and seek their care in South Atlantic Petroleum Medical Center keffi, Nasarawa State. Ethical approval was obtained from research and Ethics committee of South Atlantic Petroleum Medical Center, Keffi, Nigeria

3.3 Data Collection

A comprehensive Secondary data of those who were screened for *H. pylori* infection from May to November, 2019 was obtained from South Atlantic Petroleum Medical Center, Keffi, Nasarawa State. Which include gender, age, occupation, current history, previous history, nature of Specimen, *H. pylori* status.

3.4 Statistical Analysis

The data generated were coded, entered, validated, and analyzed using SPSS. Associations between categorical variables were tested using the chi-squared test with reports of the corresponding p-values. In some instances where there were small numbers in a given cell (<5), Fischer's exact test was used and the corresponding p-value reported. The odds ratio and the corresponding 95% confidence intervals (95% CI) were used to summarize the strength of association between *H. pylori* positivity and risk factors in a multinomial logistic regression test. The level of statistical significance for the study was set at $p < 0.05$. In all the tests, p-values less than 0.05 or near 0.05 were used as statistical association for risk factors of *H. pylori* infection.

3.5 Diagnostic tests

Diagnostic tests are indicated in patients:

- 1) With active peptic ulcer disease (duodenal or gastric),
- 2) With a history of peptic ulcer disease, who have not been previously treated,
- 3) With low-grade gastric MALT lymphoma,
- 4) Who have undergone endoscopic resection of early gastric cancer
- 5) With uninvestigated dyspepsia, younger than 55 years old (without alarm symptoms).

Available tests for the detection of *Helicobacter pylori* include:

- Antibody tests,
- Urea breath tests,

- Stool antigen tests,
- Endoscopic biopsies.

Blood tests detect the presence of antibodies of *Helicobacter pylori*. However, blood antibodies can persist years after the complete eradication of the bacteria. They may be useful in diagnosing the infection, but they are not good for a determined successful eradication.

The urea breath test (UBT) is a safe, easy, and accurate test for the detection of the presence of *Helicobacter pylori* in the stomach. Ten to twenty minutes after swallowing a capsule containing urea, a breath sample is collected and analyzed for labeled carbon dioxide breath. A positive test signifies that there is an active infection. The test becomes negative shortly after eradication. Individuals concerned with the minute amounts of radioactivity can be tested with urea labeled with heavy, nonradioactive carbon.

Endoscopy is an accurate test for diagnosing the infection as well as the inflammation and ulcers. Endoscopy also allows the determination of the severity of gastritis with biopsies as well as the presence of ulcers, MALT lymphoma and cancer. Biopsies may also be cultured in the bacteriology laboratory for the presence of *Helicobacter pylori*.

Stool sample: the test uses an antibody of *Helicobacter pylori* to determine if *Helicobacter pylori* antigen is present in the stool, which means that there is a *Helicobacter pylori* infection in the stomach. The stool test can be used to determine if the eradication has been effective after the treatment. In 2012, the FDA approved that the urea breath test was performed in children aged 3 to 17 year

CHAPTER FOUR

RESULT

4.1 Result

Chi-Square Analysis for Age and Sex Determinants of *Helicobacter pylori* Infection Status among Students of Nasarawa State University, Keffi

Hypothesis

H_1 :- There is a statistically significant relationship between the prevalence of *Helicobacter pylori* and age/sex of the students.

H_0 :- There is no statistically significant association between the prevalence and distribution of *Helicobacter pylori* with the studied parameters

Interpretation

Significance level = 0.05

Degree of freedom = $n-1$

Where,

n = No. of observations

Confidence Limits = 95%

Decision: if $P \leq 0.05$ accept H_1 ; reject H_0

If $P > 0.05$ accept H_0 ; reject H_1

4.2 Data Analysis

Table 1: Seroprevalence of *Helicobacter pylori* Infection amongst Students of NSUK in Relation to Age

Age (Years)	No. Screened	No. Infected	% Prevalence
0-20	29	15	51.7
21-40	50	29	58.0
41 and above	5	2	40.0
Total	84	46	54.8

$$X^2 = 2.7549$$

$$P = 0.2522$$

(Result not statistically significant at $P > 0.05$)

In Table 1: The highest percentage prevalence was recorded with the age bracket of (21-40) years with 58.0% while the lowest fall within the age bracket of (41 and above) with 40.0%.

Table 2: Seroprevalence of *Helicobacter pylori* Infection amongst Students of NSUK in Relation to Gender

Gender	No. Screened	No. Infected	% Prevalence
Males	37	22	59.4
Females	47	24	51.1
Total	84	46	54.8

$X^2 = 5.9605$

$P_{value} = 0.0146$

(Result is statistically significant at $P < 0.05$)

In Table 2: The males have the highest percentage prevalence of 59.4% though with the lowest number screened at 37 and 22 infected respectively while the females have the lowest percentage prevalence of 51.1% with the highest number screened at 47 and 24 infected respectively.

Basic Decision

Table 1: There is no statistically significant relationship between the age of the students and the distribution of *Helicobacter pylori* ($P > 0.05$)

Table 2: There is a statistically significant association between the distributions of *Helicobacter pylori* ($P \leq 0.05$)

Chi-Square Analysis for Occupation and History Determinants of *Helicobacter pylori* Infection Status among Students of Nasarawa State University, Keffi

Hypothesis

H₁:- There exist a statistically significant association between the prevalence of *Helicobacter pylori* infection and occupation and previous/current infection history of the students.

H₀:- There is no statistically significant association between the prevalence of *Helicobacter pylori* with occupation and history of the infection.

Basic Decision and Interpretation of Data

Confidence limit = 95%

Level of significance = 0.05

Degree of freedom = n-1; where:

n= Total number of observations

Decision: if $P \leq 0.05$ accept H₁; reject H₀

If $P > 0.05$ accept H₀; reject H₁

Table 3: Seroprevalence of *Helicobacter pylori* Infection amongst Students of NSUK in Relation to Occupation

Occupation	No. Examined	No. Positive	% Prevalence
Students	81	45	55.6
Civil Servants	3	1	33.3
Total	84	46	54.8

$$X^2 = 4.2189$$

$$P_{\text{value}} = 0.0399$$

(The result is statistically significant at $P < 0.05$)

In Table 3: The highest percentage in relation to occupation prevalence was recorded among students with 55.6% with 81 students examined and 45 tested positive respectively while the lowest percentage prevalence was recorded among civil servants with 3 examined and only one tested positive with 33.3%.

Table 4: Past and Current status of Peptic Ulcer due to *Helicobacter pylori* Infection amongst Students of NSUK

Variable	No. Identified	% Distribution
Formally infected & currently infected	25	55.6
Past infected, currently negative	15	33.3
Formally negative currently positive	21	25.0
Formally negative & currently negative	23	27.4
Total	84	100.0

Currently positive 46
Total prevalence 54.8%

$$X^2 = 1.3692$$

$$P_{\text{value}} = 0.7127$$

(Result not statistically significant at $P > 0.05$).

Table 4: There is a statistically significant association between the prevalence of *Helicobacter pylori* infection and the occupation of the students at NSUK ($P \leq 0.05$)

Table 4: There is no statistically relationship between the prevalence of *Helicobacter pylori* infection and its distribution in terms of past and current status in the students of NSUK studied at ($P>0.05$).

4.3 Discussion

The prevalence of *Helicobacter pylori* infection is high worldwide and it is more common in developing countries than the developed ones (Magalhães and Luzzza, 2006). It is a major risk factor for chronic gastritis, peptic ulcer and gastric cancer (Fock and Ang, 2010). *Helicobacter pylori* can cause severe illnesses with high morbidity and mortality rates, the complex interactions between this microbe and humans, particularly its transmission pathways to humans and reservoirs, are largely unknown (Seckae et al., 2013). However, recent report by Mitchell and Katelaris (2016) had considered *H. pylori* to be a foodborne pathogen because of its microbiological and epidemiological characteristics. Even so, Aktepe and colleagues (2011) had suggested that the accurate detection of *H. pylori* is essential for the management of patients and for the eradication of the bacterium following treatment.

The prevalence of *H. pylori* infection worldwide varies among countries and population groups in the same country. This infection is more common in developing countries where the prevalence rate ranges between 70–90% as compare to developed countries (Olokoba et al., 2013). Thus a study to ascertain the age and gender determinant of infection due to peptic ulcer amongst students of Nasarawa State University was conducted. In this present study, 84 students of varying socio-demographic characteristics were screened, of which 46 representing an overall prevalence of 54.8% were infected by *H. pylori*. The results recorded in this study are comparable to those reported elsewhere, such as those of Akbar and El-Tahary (2005), Agülo et al. (2006), Daniella et al. (2008),

Tijanni and Umar (2008), Shrestha *et al.* (2012), Campanati *et al.* (2013) and Isa *et al.* (2015).

Age-related prevalence indicates the highest occurrence of 58.0% amongst those students aged between 21–40 years old, followed closely by those within the age bracket ≤ 20 years old with a point prevalence of 51.7%. Interestingly, students within the higher age bracket had the least prevalence of 40.0% with respect to age. The determinant in relation to age shows that the highest sero-positivity is skewed towards younger students. This is in consonance to an earlier report by Amberbire *et al.* (2011) who suggested that age influence the acquisition and colonization of the intestinal walls by the causative agent of peptic ulcer in their study of the effects of *Helicobacter pylori* and helminthes infection amongst Ethiopian children. Shi *et al.* (2008) and Kato and Fujimura (2009) also note that the risk for infection due to *H. pylori* is higher in people of younger age particularly in children.

This tends to disagree with an earlier report by Al-Molged *et al.* (1990) that seroprevalence of *H. pylori* increases as the age subjects advances. Also, the low prevalence of *H. pylori* among subjects of higher age disagrees with other studies previously described (Langat *et al.*, 2006). Though, the high prevalence of *H. pylori* among children has been reported to be due to poor socio-economic condition (Langat *et al.*, 2006). Nevertheless, the seroprevalence of *H. pylori* was statistically insignificant irrespective of the ages of subject at $P > 0.05$ and this implies that age may not be a factor for high prevalence of *H. pylori*. In another related report, infected mothers or older siblings, low standards of living, and crowded households have been shown to be major risk factors for contracting *H. pylori* (Hunt *et al.*, 2011). In fact, during the past decades,

several reports indicated a correlation between *H. pylori* infection and various extra gastric disorders (Banić *et al.*, 2012).

Meanwhile, Ikeda and colleagues (2013) found high prevalence of *Helicobacter pylori* infection in middle-aged Japanese children majority of whom are college students; this correspond directly to the findings of this present study since it was specifically undertaken in a university environment. On a similar note, Kang *et al.* (2011) in their study of the risk factors for peptic ulcer infection due to *H. pylori* implicated age, diet, presence of other disease, overcrowding and certain group of people to be predisposing factors that increase vulnerability to contracting the infection. This singular cohort research reinforced the findings of this present study. Thus, proper hygiene and sanitary behaviours should be encouraged among the general population, particularly among students living in crowded houses.

This study observed higher prevalence amongst the male students (59.4%) than the females with a relatively lower prevalence rate of 51.1%. This corroborates the works of Xu *et al.* (2000) and Ndipet *et al.* (2009) who reported a significantly higher prevalence rate among the males. Ahmad *et al.* (1997) reported a much higher seroprevalence rate of 92% among male subjects in his pilot serological study of *H. pylori* in Bangladesh which concur with the finding of the present work. Although most studies as observed in the literatures suggest that gender don't necessarily influence the seroprevalence rate, studies such as those of Mégraud *et al.* (1990), Granström *et al.* (1997), Naficy *et al.* (2000), Dore *et al.* (2002), Akbar and El-Tahary (2005), Shi *et al.* (2008) and Etukudo *et al.* (2012). Conversely, Tijjani and Umar (2008), Nwodo *et al.* (2009) and Rasmi *et al.* (2009) refuted the arguments of the researchers mentioned above by demonstrating from their respective studies that both males and females are infected almost at the same rate.

CHAPTER FIVE

SUMMARY, CONCLUSION AND RECOMMENDATIONS

5.1 Summary

1. This study sought to identify age and gender determinants in the acquisition of peptic ulcer infection due to *Helicobacter pylori* amongst students of Nasarawa State University Keffi.
2. A total of 84 students were selected at random and screened using the rapid diagnostic test strip, of which 46(54.8%) were found to harbour the bacteria.
3. In terms of age, the infection is highest amongst students aged 21–40 years (58.0%), followed by those aged 0–20 years (51.7%) and lastly those aged ≥ 41 year (40.0%). There is no statistical significant relationship with age at $P > 0.05$.
4. In relation to gender, the males (59.4%) were more infected than the females (51.1%); although gender is statistically significant to the prevalence of *H. pylori* at $P < 0.05$.

5.2 Conclusion

Seroprevalence of *H. pylori* was high in this study, though it was less than other studies reported elsewhere and in view of this, it may have public health implication. The infection was highest amongst the younger students and in males than in the female students. However, again this study does not influence the acquisition of peptic ulcer infection statistically ($P = 0.2522$); while a statistically significant association was observed for the gender of the students ($P = 0.0146$).

This study therefore revealed a higher seroprevalence of *H. pylori* among some selected students of Nasarawa State University Keffi. One of the major justification of this study is that it is conducted among a general population of the study area, not among people in a hospital settings (whom of course are there due to sicknesses), and can perhaps be a true representation of the prevalence of *H. pylori* among the general population within the university community in particular. Nonetheless, a community study is desirable as this will give a more true representation of the prevalence.

5.3 Recommendations

In view of the high seroprevalence of the infection recorded among the subjects in the study area, a more thorough epidemiological survey is warranted to determine the prevalence of *H. pylori* in Keffi town in particular and Nasarawa State in general. This in turn will open avenues for more studies about the risk factors and mode of transmission of *H. pylori*. Also, various diagnostic tests for *H. pylori* infection may give an ambiguous results and the use of multiple tests may help to provide a more accurate diagnosis of *H. pylori* infection.

Although, in spite of the introduction of the first, second and third line therapies for *H. pylori* treatment and possible eradication; their eradication rate has not reached 100%. Antibiotic resistance is still a problem in many countries including Nigeria. To face treatment failures, several third-line 'rescue' therapies have been tried. This third-line therapy has not been used in many countries. Therefore further trials are still needed to get a better *H. pylori* eradication rate through a cheap and effective treatment regimen. It is also suggested that some medicinal plants with anti-*Helicobacter pylori* activity should be considered as alternatives for ulcer therapy; the plants include extracts of *Allium sativum*, *Curcuma longa*, *Mallotus philippinesis*, *Sapindus mukarossi* and *Rheum emodii*.

REFERENCES

- Agüلولu, S., Turhanolu, M., Eskimez, S. and Tacir, I. (2006). Detection of *Helicobacter pylori* colonization in human dental plaques and saliva of patients with chronic gastritis. *BiotechnolBiotechnolEq.* 20: 173-178.
- Ahmad, M.M., Rahman, M., Rumi, A.K., Islam, S., Hug, F. and Jinnah, F. (1997). Prevalence of *Helicobacterpylori* in asymptomatic population -a pilot serological study in Bangladesh. *J. Epidemiol.* 7: 251-254.
- Akbar, D.H. and El Tahawy, A.T. (2005). *Helicobacterpylori* infection at a University Hospital in Saudi Arabia, prevalence, comparison of diagnostic modalities and endoscopic findings. *Indian Journal of Pathology and Microbiology.* 48(2): 181-185.
- Aktepe, O.C., Çiftçi, İ.H., Şafak, B., Uslan, İ. and Dilek, F.H. (2011). Five methods for detection of *Helicobacterpylori* in the Turkish population. *World Journal of Gastroenterology.* 17(47): 5172-5176.
- Al-Molged, M.A., Evans, D.G., Evans, D.J. Jr, Abdulghani, M.E., Adam, E. and Malaty, H.M. (1990). Prevalence of *Helicobacter* (formerly *Campylobacter*) *pylori* infection in Saudi Arabia, and comparison of those with and without upper gastrointestinal symptoms. *Am.J. Gastroenterology.* 85: 944-948.
- Amberbir, A., Medhin, G., Erku, W., Alem, A., Simms, R., Robinson, K., Fogarty, A., Britton, J., Venn, A. and Davey, G. (2011). Effects of *Helicobacterpylori*, geohelminth infection and selected commensal bacteria on the risk of allergic disease and sensitization in 3-year-old Ethiopian children. *ClinicalExperiments and Allergy.* 41: 1422-1430.
- Banić, M., Franceschi, F., Babić, Z. and Gasbarrini, A. (2012). Extragastric manifestations of *Helicobacterpylori* infection. *Helicobacter.* 17(1): 49-55.
- Campanati, A., Gesuita, R., Giannoni, M., Piraccini, F., Sandroni, L., Martina, E., Conocchiari, L., Bendia, E., Di Sario, A. and Offidani, A. (2013). Role of small intestinal bacterial overgrowth and *Helicobacterpylori* infection in chronic spontaneous urticaria: a prospective analysis. *ActaDermVenereol.* 93: 161-164.

- Daniela, B., Carlo-Federico, Z., Darren, P.L., Alessia, S., Alberto, M. and Joanne, L.R. (2008). Clinical Relevance of *Helicobacter pylori* *cagA* and *vacA* Gene Polymorphisms. *Gastroenterology*. 135: 91-99.
- Dore, M.P., Leandro, G., Realdi, G., Sepulveda, A.R. and Graham, D.Y. (2002). Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of *Helicobacter pylori* therapy: A meta-analytical approach. *Dig. Dis. Sci.* 45: 68-76
- Etukudo, O.M., Ikpeme, E.E., and Ekanem, E.E. (2012). Sero-epidemiology of *Helicobacter pylori* infection among children seen in a tertiary hospital in Uyo, Southern Nigeria. *The Pan African Medical Journal*. 12: 39.
- Fock, K.M. and Ang, T.L. (2010). Epidemiology of *Helicobacter pylori* infection and gastric cancer in Asia. *Journal of Gastroenterology and Hepatology*. 25(3): 479-486.
- Granström, M., Tindberg, Y. and Blennow, M. (1997). Sero-epidemiology of *Helicobacter pylori* infection in a cohort of children monitored from 6 months to 11 years of age. *J. Clin. Microbiol.* 35(2): 468-470.
- Hunt, R.H., Xiao, S.D., Megraud, F., Leon-Barua, R., Bazzoli, F., Van der Merwe, S., Vaz Coelho, L.G., Fock, M., Fedail, S. and Cohen, H. (2011). *Helicobacter pylori* in developing countries. World Gastroenterology Organization Global Guideline. *Journal of Gastrointestinal and Liver Diseases*. 20: 299–304.
- Ikeda, A., Iso, H., Sasazuki, S., Inoue, M., Tsugane, S. and JPHC Study Group. (2013). The combination of *Helicobacter pylori*- and cytotoxin- associated gene-A seropositivity in relation to the risk of myocardial infarction in middle-aged Japanese: The Japan Public Health Center-based study. *Atherosclerosis*. 230: 67-72.
- Isa, M.A., Onuegbu, C.U., Bulakarima, A.U., Kolo, B.S., Muhammad, I. and Dawud, H. (2015). Seroprevalence of *Helicobacter pylori* among Pregnant Women attending Ante-Natal Clinic in University of Maiduguri Teaching Hospital, Borno State, Nigeria. *Bioglobia*. 2(2): 18-23.
- Kang, J.M., Kim, N., Lee, B.H., Park, H.K., Jo, H.J., Shin, C.M., Lee, S.H., Park, Y.S., Hwang, J.H., Kim, J.W., Jeong, S.H., Lee, D.H., Jung, H.C. and Song, I.S. (2011). Risk factors

- for peptic ulcer bleeding in terms of *Helicobacter pylori*, NSAIDs, and antiplatelet agents. *Scandinavian Journal of Gastroenterology*. 46: 1295-1301
- Kato, S. and Fujimura, S. (2010). Primary antimicrobial resistance of *Helicobacter pylori* in children during the past 9 years. *Paediatric International*. 52: 187-190.
- Langat, A.C., Ogutu, E., Kamenwa, R. and Simiyu, D.E. (2006). Prevalence of *Helicobacter pylori* in children less than three years of age in health facilities in Nairobi Province. *East African Medical Journal*. 83(9): 471-477.
- Magalhães, Q.D. and Luzzza, F. (2006). Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 1(11):1-5.
- Megraud, F. (1998). Epidemiology and mechanism of antibiotic resistance in *Helicobacter pylori*. *Gastroenterology*. 115: 1278-82.
- Megraud, F., Brassens-Rabbe, M.P., Denis, F., Belbowri, A. and Hoa, D.G. (1989). Seroepidemiology of *Campylobacter pylori* infection in various populations. *Journal of Clinical Microbiology*. 27: 1870-1873.
- Mitchell, H. and Katelaris, P. (2016). Epidemiology, clinical impacts and current clinical management of *Helicobacter pylori* infection. *Medical Journal of Australia*. 204: 376-380
- Naficy, A.B., Frenck, R.W., Abu-Elyazeed, R., Kim, Y., Rao, M.R., Savarino, S.J., Wierzb, T.F., Hall, E. and Clemens, J.D. (2000). Sero-epidemiology of *Helicobacter pylori* infection in a population of Egyptian children. *International Journal of Epidemiology*. 29(5): 928-932.
- Ndip, R.N., Malange, E.A., Akoachere, T.K., MacKay, G.W., Titanji, K.P. and Weaver, T.L. (2009). *Helicobacter pylori* antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: A pilot study. *Trop. Med. Int. Health*. 9(9): 1036-1040.
- Nwodo, E.N., Yakubu, S.E., Jatau, E.D. and Yabaya, A. (2009). Seroprevalence of *Helicobacter pylori* infection in patients with gastritis and peptic ulcer disease in Kaduna, Kaduna State, Nigeria. *African Journal of Basic & Applied Sciences*. (5-6): 123-128.

- Olokoba, A.B., Obateru, O.A. and Bojuwoye, M.O. (2013). *Helicobacter pylori* eradication therapy: A review of current trends. *Niger.Med.J.* 54: 1-4.
- Rasmi, Y., Sadreddini, M., Peirovi, T., Jamali, M., Khosravifar, F., Dadkhah, A., Fatemi, F., Rahmati, M., Zargari, M. and Sharifi, R. (2009). Frequency of ABO blood group in peptic ulcer disease in Iranian subjects. *Pakistan Journal of Biological Sciences.* 12(13): 991-993.
- Secka, O., Berg, D.E., Antonio, M., Corrah, T., Tapgun, M., Walton, R., Thomas, V., Galano, J.J., Sancho, J. and Adegbola, R.A. (2013) Antimicrobial susceptibility and resistance patterns among *Helicobacter pylori* strains from The Gambia, West Africa. *Antimicrobial Agents and Chemotherapy.* 57: 1231–1237.
- Shi, R., Xu, S. and Zhang, H. (2008). Prevalence and risk factors in *Helicobacter pylori* infection in Chinese populations. *Helicobacter.* 13: 157-165.
- Shrestha, S., Paudel, P., Pradhan, G.B., Shrestha, L. and Bhattachan, C.L. (2012) Prevalence study of *H. pylori* infection in dyspeptic patients coming to Nepal Medical College Teaching Hospital, Jorpati, Kathmandu. *Nepal Medical College Journal.* 14: 229–233.
- Tijjani, B. And Umar, A. (2008). Peptic ulcer disease and *Helicobacter pylori* infection at Kano, Nigeria. *The Internet Journal of Gastroenterology.* 8(1): 117-125.
- Xu, C., Chen, S., Jiang, S. and Xu, J. (2000). Sero-epidemiology of *Helicobacter pylori* infection among asymptomatic Chinese children. *World Journal of Gastroenterology.* 6: 759-761.
- Aboderin, O.A., Abdu, A.R., Odetoyin, B., Okeke, I.N., Lawal, O.O., Ndububa, D.A., Agbakwuru, A.E., Lamikanra, A., (2007). Antibiotic resistance of *Helicobacter pylori* from patients in Ile-Ife, South-west, Nigeria. *African Health Science*; 7:143-7.
- Achtman, M. and Suerbaum, S. (2000). Sequence variation in *Helicobacter pylori*. *Trends Microbiol.* 8:57–58
- Adlekha, S., Chadha, T., Krishnan, P., Sumangala, B. (2013). Prevalence of *Helicobacter pylori* infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in kerala, India. *Ann Med Health Sci Res*; 3:559–63.
- Ahmad, M.M., Rahman M., Rumi A.K., Islam S., Huq F., Chowdhury M.F., Jinnah F., Morshed M.G., Hassan M.S., Khan A.K., Hasan M., (1997). Prevalence of *Helicobacter pylori* in asymptomatic population – A pilot serological study in Bangladesh. *Journal of Epidemiology*; 7:251-4.

- Akamatsu, T., Tabata, K., Hirong, M., Kawakami, H. and Uyeda, M. (1996). Transmission of *Helicobacter pylori* infection via flexible fiberoptic endoscopy. *American Journal of Infection Control* 24:396–401.
- Allaker, R.P., Young, K.A., Hardie, J.M., Domizio, P., Meadows, N.J., (2002). Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: Evidence for possible oral-to-oral transmission. *Journal of Medical Microbiology*; 51:312–7.
- Alvarado-Esquivel C. (2013). Seroepidemiology of *Helicobacter pylori* infection in Tepehuanos aged 15 years and older in Durango, Mexico. *Journal of Pathology*; 2013:243246.
- Alvarado-Esquivel, C. (2013) Seroepidemiology of *Helicobacter pylori* infection in pregnant women in rural durango, Mexico. *Int J Biomed Sci*; 9:224–9.
- Amieva, M.R., Vogelman, R., Covacci, A., Tompkins, L.S., Nelson, W.J. and Falkow, S. (2003) Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science*; 300(5624):1430–1434.
- Amieva, M.R., El-Omar, E.M. (2008). "Host-bacterial interactions in *Helicobacter pylori* infection". *Gastroenterology*. 134 (1): 306–23.
- Ashton-Key, M., Diss, T. C. and Isaacson, P. G. (1996). Detection of *Helicobacter pylori* in gastric biopsy and resection specimens. *J. Clin. Pathol.* 49:107–111.
- Baako B.N., Darko R. (1996). Incidence of *Helicobacter pylori* infection in Ghanaian patients with dyspeptic symptoms referred for upper gastrointestinal endoscopy. *West African Journal of Medicine* ; 15:223–7.
- Backert, S. and Selbach, M. (2008). Role of type IV secretion in *Helicobacter pylori* pathogenesis. *Cell Microbiol.* 10(8):1573–1581.
- Bashir M.T., Ali B. U., (2009). Peptic ulcer disease and *Helicobacter pylori* infection at Kano, Nigeria. *Internet Journal of Gastroenterology* ; 8:1–3.
- Bastos, J., Peleteiro, B., Pinto, H., Marinho, A., Guimaraes, J.T., Ramos, E., La Vecchia, C., Barros H. and Lunet, N. (2013). Prevalence, incidence and risk factors for *Helicobacter pylori* infection in a cohort of Portuguese adolescents (EpiTeen). *Dig Liver Dis*; 45:290–5.
- Bastos, J., Peleteiro, B. and Barros R, (2013). Sociodemographic determinants of prevalence and incidence of *Helicobacter pylori* infection in Portuguese adults. *Helicobacter*; 18(6):413–22.
- Bateson, M.C., (1993). Cigarette smoking and *Helicobacter pylori* infection. *Postgraduate Medical Journal*; 69:41–4.
- Becker, S. I., Smalligan, R. D., Frame, J. D., Kleanthous, H., Tibbitts, T.J., Monath T.P., Hyams, K.C., (1999). Risk of *Helicobacter pylori* infection among long-term residents in

developing countries. *The American Journal of Tropical Medicine and Hygiene*, vol. 60, no. 2, pp. 267–270.

- Benajah, D.A., Lahbabi, M., Alaoui, S., El Rhazi, K., El Abkari, M., Nejari, C., Amarti, A., Bennani, B., Mahmoud, M. and Ibrahim, S.A. (2013). Prevalence of *Helicobacter pylori* and its recurrence after successful eradication in a developing nation (Morocco). *Clin Res Hepatol Gastroenterol*; 37:519–26.
- Benberin, V., Bektayeva, R., Karabayeva, R., Lebedev, A., Akemeyeva, K., Paloheimo, L. and Syrjänen, K. (2013). Prevalence of *H. pylori* infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. *Anticancer Res*; 33:4595–602.
- Blaser, M. J. (1990). *Helicobacter pylori* and the pathogenesis of gastroduodenal inflammation. *J. Infect. Dis.* 161:626–633.
- Blaser, M. J. and Atherton, J. C. (2004). *Helicobacter pylori* persistence: biology and disease. *J. Clin. Invest.* 113:321–333.
- Boneca, I. G., de Reuse, H., Epinat, J. C., Pupin, M., Labigne, A. and Moszer, I. (2003). A revised annotation and comparative analysis of *Helicobacter pylori* genomes. *Nucleic Acids Res.* 31:1704–1714.
- Brandt, S., Kwok, T., Hartig, R., König, W. and Backert, S. (2005). NF- κ B activation and potentiation of proinflammatory responses by the *Helicobacter pylori* CagA protein. *Proc Natl Acad Sci U S A*; 102(26):9300–9305.
- Bugaytsova, Jeanna, A., Björnham, Oscar, Chernov, Yevgen, A., Gideonsson, P., Henriksson, S., Mendez, M., Sjöström, R., Mahdavi, J. Shevtsova, A. (2017). "Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392239>). *Cell Host & Microbe*. 21 (3): 376–389.
- Censini, S., Lange, C. and Xiang, Z. (1996). Cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci U S A*; 93(25):14648–14653.
- Chan, W.Y., Hui, P.K., Leung, K.M., Chow, J., Kwok, F. and Ng, C.S. (1994). "Coccoid forms of *Helicobacter pylori* in the human stomach". *Am J Clin Pathol*. 102 (4): 503–7.
- Covacci A. and Rappuoli R. ((2000). Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. *J Exp Med*; 191(4):587–592.
- Cullen, J. E. Collins, J. Christiansen, K. J. Epis, J. Warren, J. R. and Cullen, K. J. (1993). Abstract from the Digestive Diseases Week 1993, *Gastroenterology* 104:A60,
- Cutler, A. F., Havstad, S. Ma, C. K. Blaser, M. J. Perez-Perez, G. I. and Schubert, T. T. (1995).

- Accuracy of invasive and noninvasive tests to diagnose *Helicobacter pylori* infection. *Gastroenterology* 109:136–141.
- deJonge, R., Kuipers, E. J., Langeveld, S. C., Loffeld, R. J., Stoof, J., van Vliet, A. H. and Kusters, J. G. (2004). The *Helicobacter pylori* plasticity region locus jhp0947–jhp0949 is associated with duodenal ulcer disease and interleukin-12 production in monocyte cells. *FEMS Immunol. Med. Microbiol.* 41:161–167.
- Den Hollander, W.J., Holster, I.L. and den Hoed, C.M., (2013). Ethnicity is a strong predictor for *Helicobacter pylori* infection in young women in a multi-ethnic European city. *J GastroenterolHepatol*; 28:1705–11.
- Debowski, Aleksandra, W., Walton, Senta M., Chua, Eng-G., Tay, Alfred Chin-Yen, Liao, Tingting; Lamichhane, B., Himbeck, R., Stubbs, Keith A., Marshall, and Barry, J. (2017). "*Helicobacter pylori* gene silencing in vivo demonstrates urease is essential for chronic infection" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500380>). *PLOS Pathogens*.13 (6): e1006464.
- Dorji, D., Dendup, T., Malaty, H.M., Wangchuk, K., Yangzom, D. and Richter, J.M.(2014). Epidemiology of *Helicobacter pylori* in Bhutan: the role of environment and Geographic location. *Helicobacter*;19:69–73
- Dubois, A., Fiala, N., Heman-Ackah, L. M., Drazek, E. S., Tarnawski, A., Fishbein, W. N., Perez-Perez, G. I. and Blaser, M. J. (1994). Natural gastric infection with *Helicobacter pylori* in monkeys: a model for spiral bacterial infection in humans. *Gastroenterology* 106:1405–1417.
- El Dine, S., Mubarak, M., Salama, R., (2008). Low seroprevalence of anti-CagA antibodies inspite of high seroprevalence of anti-*H.pylori* antibodies in Rural Egyptian Community. *Research Journal of Medical Sciences*; 3:118–123.
- El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C. C., Rothman, N., Lanyon, G., Martin, M., Fraumeni, J. F. and
- Rabkin, C. S. (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 404:398–402.
- el-Zimaity, H. M., Graham, D. Y., al-Assi, M. T., Malaty, H., Karttunen, T. J., Graham, D. P., Huberman, R. M. and Gent, R. M. (1996). Interobserver variation in the histopathological assessment of *Helicobacter pylori* gastritis. *Hum. Pathol.* 27:35–41.
- Eshraghian, (2014). Epidemiology of *Helicobacter pylori* infection among the healthy population in iran and countries of the eastern mediterranean region: a systematic review of prevalence and risk factors. *World Journal of Gastroenterology*: WJG, vol. 20, no. 46, pp. 17618–17625.

- Etukudo, O.M., Ikpeme, E.E., Ekanem, E.E., (2012). Seroepidemiology of *Helicobacter pylori* infection among children seen in a tertiary hospital in Uyo, Southern Nigeria. *Pan African Medical Journal* ;12:39.
- Falush, D., Kraft,C.,Taylor,N. S., Correa,P.,Fox,J. G.,Achtman, M. and Suerbaum S.(2001). Recombination and mutation during long-term gastric colonization by *Helicobacter pylori*: estimates of clock rates, recombination size, and minimal age. *Proc. Natl. Acad. Sci. USA* 98:15056–15061.
- Falush, D., Wirth, T., Linz,B. Pritchard,J. K Stephens,M. Kidd, M Blaser,M. J. Graham,D. Y.
- Vacher, S. Perez-Perez, G. I. Yamaoka,Y. Megraud,F.Otto, K. Reichard,U. Katzowitsch, E. Wang,X..Achtman,M and S. Suerbaum (2003). Traces of human migrations in *Helicobacter pylori* populations. *Science* 299:1582–1585.
- Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., Parkin, D. M.,(2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *International Journal of Cancer*, vol. 127, no. 12, pp. 2893–2917,.
- Fiedorek, S. C., Malaty, H. M., Evans,D. L.,Pumphrey,C. L., Casteel,H. B., Evans,D. J. and Graham, D. Y. (1991). Factors influencing the epidemiology of *Helicobacter pylori* infection in children. *Pediatrics* 88:578–582.
- Figueiredo, C., van Doorn, L.J. and Nogueira,C.(2001). *Helicobacter pylori* genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. *Scand J Gastroenterol.*; 36(2):128–135.
- Forman, D., Sitas, F., Newell, D.G., Stacey, A.R., Boreham, J., Peto, R., Campbell, T.C., Li, J., Chen, J., (1990). Geographic association of *Helicobacter pylori* antibody prevalence and gastric cancer mortality in rural China. *International Journal of Cancer*; 46:608-11.
- Fox, J. G., Batchelder, M., Marini, R.,Yan, L., Handt, L., Li, X., Shames, B., Hayward, A., Campbell, J. andMurphy, J. C. (1995). *Helicobacter pylori* induced gastritis in the domestic cat. *Infection and Immunity*. 63:2674–2681.
- Franco, A.T., Johnston, E. and Krishna, U.(2008). Regulation of gastric carcinogenesis by *Helicobacter pylori* virulence factors. *Cancer Res.*; 68(2):379–387.
- Franco, A.T., Israel, D.A. and Washington, M.K.(2005). Activation of beta catenin by carcinogenic *Helicobacter pylori*. *Proc Natl AcadSci U S A.*; 102(30):10646–10651.
- Genta,R. M. and. Graham, D. Y.(1994). Comparison of biopsy sites for the histopathologic diagnosis of *Helicobacter pylori*: a topographic study of H. pylori density and distribution. *Gastrointest. Endosc.* 40:342–345.
- Genta, R. M. (2002). Review article: after gastritis an imaginary journey into a *Helicobacter* free world. *Alimentary Pharmacology and Therapeutics*. 16(Suppl. 4): 89–94.
- Ghasemi-Kebria, F., Ghaemi, E., Azadfar, S., Roshandel, G.(2013). Epidemiology of *Helicobacter pylori* infection among Iranian children. *Arab J Gastroenterol*; 14:169–72.

- Graham, D. Y., Opekun, A. R., Osato, M. S., El-Zimaity, H. M., Lee, C. K., Yamaoka, Y., Qureshi, W. A., Cadoz, M. and Monath, T. P. (2004). Challenge model for *Helicobacter pylori* infection in human volunteers. *Gut* 53:1235–1243.
- Granstrom, M., Tindberg, Y. and Blennow, M. (1997). Seroepidemiology of *Helicobacter pylori* infection in a cohort of children monitored from 6 months to 11 years of age. *J. Clin. Microbiol.* 35:468–470.
- Han, S. W., Flamm, R., Hachem, C. Y., Kim, H. Y., Clarridge, J. E., Evans, D. G., Beyer, J., Drnec, J. and Graham, D. Y. (1995). Transport and storage of *Helicobacter pylori* from gastric mucosal biopsies and clinical isolates. *Eur. J. Clin. Microbiol. Infect. Dis.* 14:349–352.
- Hachem, C. Y., Clarridge, J. E., Evans, D. G. and Graham, D. Y. (1995). Comparison of agar based media for primary isolation of *Helicobacter pylori*. *J. Clin. Pathol.* 48:714–716.
- Hanafi, M. I. and Mohamed, A. M. (2013). *Helicobacter pylori* infection: seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. *J Egypt Public Health Assoc*; 88:40–5.
- Hatakeyama, M. (2004). Oncogenic mechanisms of the *Helicobacter pylori* Cag protein. *Nature Rev Cancer*; 4(9):688–694.
- Hatakeyama, M. (2009). *Helicobacter pylori* and gastric carcinogenesis. *J Gastroenterol*; 44(4):239–248.
- Heuermann, D., and Haas, R. (1995). Genetic organization of a small cryptic plasmid of *Helicobacter pylori*. *Gene* 165:17–24.
- Higashi, H., Tsutsumi, R. and Muto, S. (2002) SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science*. 295(5555):683–686.
- Holtmann, G., Cain, C. and Malfertheiner, P. (1999). Gastric *Helicobacter pylori* infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. *Gastroenterology* 117:11–16.
- Ilver, D., Arnqvist, A., Ogren, J., Frick, I. M., Kersulyte, D., Incecik, E. T., Berg, D. E., Covacci, A., Engstrand, L. and Borén, T. (1998). "*Helicobacter pylori* adhesin binding fucosylated histo-blood group antigens revealed by retagging". *Science*. 279 (5349): 373–7. ◦
- Jemikajah, D. J., Okogun, G. R., (2014). Health point prevalence of *Helicobacter pylori* in central hospital, Warri, Nigeria. *African Journal of Cell Pathology*; 3:57-60.
- Josenhans, C., Eaton, K. A., Thevenot, T., and Suerbaum, S. (2000). "Switching of Flagellar Motility in *Helicobacter pylori* by Reversible Length Variation of a Short Homopolymeric Sequence Repeat in *fliP*, a Gene Encoding a Basal Body Protein" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC98385>). *Infect Immun.* 68 (8): 4598–603.

- Kansau, I., Raymond, J., Bingen, E., Courcoux, P., Kalach, N., Bergeret, M., Briami, N., Dupont, C. and Labigne, A. (1996). Genotyping of *Helicobacter pylori* isolates by sequencing of PCR products and comparison with the RAPD technique. *Res. Microbiol.* 147:661–669.
- Katoh, M., Saito, D., Noda, T., Yoshida, S., Oguro, Y., Yazaki, Y., Sugimura, T. and Terada, M. (1993). *Helicobacter pylori* may be transmitted through gastrofiberscope even after manual hyamine washing. *Japanese Journal of Cancer Research.* 84:117–119.
- Kelly, S. M., Pitcher, M. C., Farmery, S. M. and Gibson, G. R. (1994). Isolation of *Helicobacter pylori* from feces of patients with dyspepsia in the United Kingdom. *Gastroenterology* 107:1671–1674.
- Kim, J.H., Kim, H.Y. and Kim, N.Y. (2001). Seroepidemiological study of *Helicobacter pylori* infection in asymptomatic people in South Korea. *J Gastroenterol Hepatol*; 16:969–75.
- Klein, P. D., Graham, D. Y., Gaillour, A., Opekun, A. R. and Smith, E. O. (1991). Water source as risk factor for *Helicobacter pylori* infection in Peruvian children. *Lancet* 337:1503–1506.
- Kuipers, E. J., Uytterlinde, A. M., Pena, A. S., Hazenberg, H. J., Bloemena, E., Lindeman, J., Klinkenberg-Knol, E. C. and Meuwissen, S. G. (1995). Increase of *Helicobacter pylori*-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. *Am. J. Gastroenterol.* 90:1401–1406.
- Kuipers, E. J., Israel, D. A., Kusters, J. G., Gerrits, M. M., Weel, J., van Der Ende, A., van Der Hulst, R. W., Wirth, H. P., Hook-Nikanne, J., Thompson, S. A. and Blaser, M. J. (2000). Quasispecies development of *Helicobacter pylori* observed in paired isolates obtained years apart from the same host. *J. Infect. Dis.* 181:273–282.
- Laine, L., Cohen, H., Sloane, R., Marin-Sorensen, M. and Weinstein, W. M. (1995). Interobserver agreement and predictive value of endoscopic findings for *H. pylori* and gastritis in normal volunteers. *Gastrointest. Endosc.* 42: 420–423.
- Laine, L., Estrada, R., Trujillo, M. and Emami, S. (1997). Randomized comparison of ranitidine bismuth citrate (RBC) based triple therapies for *H. pylori* (HP). *Gastroenterology* 112:A192.
- Lehours, P., Menard, A., Dupouy, S., Bergey, B., Richy, F., Zerbib, F., Ruskone-Fourmesttraux, A., Delchier, J. C. and Megraud, F. (2004). Evaluation of the association of nine *Helicobacter pylori* virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. *Infect. Immun.* 72:880–888.
- Leunk, R. D., Johnson, P. T., David, B. C., Kraft, W. G. and Morgan, D. R. (1988). Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J. Med. Microbiol.* 26:93–99.
- Lim, S.H., Kwon, J.W. and Kim, N. (2013). Prevalence and risk factors of *Helicobacter pylori* infection in Korea: nationwide multicenter study over 13 years. *BMC Gastroenterol*; 13:104.
- Mahdavi, J., Sonden, B., Hurtig, M., Olfat, F. O., Forsberg, L., Roche, N., Angstrom, J., Larsson,

- T.,Teneberg,S.,Karlsson,K. A.,Altraja,S.,Wadstrom,T.,Kersulyte,D., Berg,D. E. Dubois,A., Petersson, K. E., Magnusson, T.,Norberg, F., Lindh, B. B.,Lundskog, A., Arnqvist, L.,Hammarstrom, C. and Boren, T.(2002). *Helicobacter pylori* SabAadhesin in persistent infection and chronic inflammation. *Science* 297:573–578.
- Malaty, H. M., Graham,D. Y.(1994). Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection. *Gut* 35:742–745.
- Malaty, H. M., Engstrand, L., Pedersen, N. L., Graham, D. Y., (1994). *Helicobacter pylori* infection: genetic and environmental influences. A study of twins, *Annals of Internal Medicine*, vol. 120, no. 12, pp. 982–986.
- Malaty, H. M., Graham,D. Y. Wattigney,W. A. Srinivasan,S. R. Osato,M. and Berenson, G. S. (1999). Natural history of *Helicobacter pylori* infection in childhood: 12-year follow-up cohort study in a biracial community. *Clin. Infect. Dis.* 28:279–282.
- Malaty, H. M., Engstrand, L., Pedersen,N. L. and Graham, D. Y.(1994). *Helicobacter pylori* infection: genetic and environmental influences. A study of twins. *Ann. Intern. Med.* 120:982–986.
- Malu, A.O., Ani, A.E., Bello, S.S., (2000).The prevalence of *Helicobacter pylori* in dyspeptic patients from the Jos Plateau, Nigeria. *Nigeria Medical Journal*; 41:1-3.
- Mana, F, Vandebosch, S., Miendje,Deyi, V., Haentjens P. andUrbain, D. (2013). Prevalence of and risk factors for H. pylori infection in healthy children and young adults in Belgium anno 2010/ 2011. *ActaGastroenterol Belg*;76:381–5.
- Mathewos, B., Moges, B. andDagnew, M. (2013).Seroprevalence and trend of *Helicobacter pylori* infection in Gondar University Hospital among dyspeptic patients, Gondar, North West Ethiopia. *BMC Res Notes*; 6:346.
- Mitchell, H. M., Lee, A. and Carrick, J. (1989). Increased incidence of *Campylobacter pylori* infection in gastroenterologists: further evidence to support person-to-person transmission. *Scand. J. Gastroenterol.* 24:396– 400.
- Mobley and Harry, L. T., Mendz, George, L. Hazell, and Stuart, L. (2001). *Helicobacter pylori*: Physiology and Genetics (<https://www.ncbi.nlm.nih.gov/books/NBK2417/>). Washington (DC): ASM Press. ISBN 978-1-55581-213-3.
- Mohammed, M., Rahman, Shafiqul, A., Sarker, Pradip, K., Bardhan, Pius Hildebrand, Chris, Beglinger Klaus, G.Y.R., (V1996). *Helicobacter pylori* infection in the young in Bangladesh: Prevalence, socioeconomic and nutritional aspects,” *International Journal of Epidemiology*, vol. 25, no. 4, pp. 894–898.
- Morris, A.J., Ali, M.R., Nicholson, G.I., Perez-Perez, G.I., Blaser, M.J.,(1991). Long-term follow-up of voluntary ingestion of *Helicobacter pylori*. *Annals of Internal Medicine* ;114:662-3.
- Murata-Kamiya, N., Kurashima, Y. andTeishikata, Y,. (2007) *Helicobacter pylori* CagA interacts with E-cadherin and deregulates the b-catenin signal that promotes intestinal trans differentiation in gastric epithelial cells. *Oncogene*. 26(32):4617–4626.

- NIH Consensus Conference. (1994). *Helicobacter pylori* in peptic ulcer disease. NIH Consensus Development Panel on *Helicobacter pylori* in peptic ulcer disease. *JAMA* 272:65–69.
- Neugut, A. I., Hayek, M. and Howe, G. (1996). Epidemiology of gastric cancer. *Semin. Oncol.* 23:281–291.
- Nomura, A., Stemmermann, G. N., Chyou, P. H., Perez-Perez, G. I. and Blaser, M. J. (1994). *Helicobacter pylori* infection and the risk for duodenal and gastric ulceration. *Ann. Intern. Med.* 120:977–981.
- Occhialini, A., Marais, A., Alm, R., Garcia, F., Sierra, R. and Megraud, F. (2000). Distribution of open reading frames of plasticity region of strain J99 in *Helicobacter pylori* strains isolated from gastric carcinoma and gastritis patients in Costa Rica. *Infect. Immun.* 68:6240–6249.
- Odenbreit, S., Puls, J., Sedlmaier, B., Gerland, E., Fisher, W., Haas, R. (2000). Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science*. 287(5457):1497–1500
- Ogihara, A., Kikuchi, S., Hasegawa, A., Kurosawa, M., Miki, K., Kaneko, E. and Mizukoshi, H., (2000). Relationship between *Helicobacter pylori* infection and smoking and drinking habits. *Journal of Gastroenterology Hepatology*; 15:271–6.
- Olokoba, A.B., Gashau, W., Bwala, S., Adamu, A. and Salawu, F.K. (2013). *Helicobacter pylori* infection in Nigerians with dyspepsia. *Ghana Med J*; 47:79–81.
- Ozaydin, N., Turkyilmaz, S.A. and Cali, S. (2013). Prevalence and risk factors of *Helicobacter pylori* in Turkey: a nationally-representative, cross-sectional, screening with the (1)(3)C-Urea breath test. *BMC Public Health*; 13:1215.
- Pacheco, S.L., Ogata, S.K., Machado, R.S., Patricio, F.R., Pardo, M.L. and Kawakami, E. (2013). Diagnosis of *Helicobacter pylori* infection by means of reduced-dose (13) C-urea breath test and early sampling of exhaled breath. *J Pediatr Gastroenterol Nutr*; 57:607–11.
- Perez-Perez, G. I., Olivares, A. Z., Foo, F. Y., Foo, S., Neusy, A. J., Ng, C., Holzman, R. S., Marmor, M. and Blaser, M. J. (2005). Seroprevalence of *Helicobacter pylori* in New York City populations originating in East Asia. *Journal of Urban Health* 82:510–516.
- Perez-Perez, G. I., D. Rothenbacher, D. H. Brenner, H. (2004). Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 9(Suppl. 1):1–6.
- Perez-Perez, G. I., Sack, R. B., Reid, R., Santosham, M., Croll, J. and Blaser, M. J. (2003). Transient and persistent *Helicobacter pylori* colonization in Native American children. *J. Clin. Microbiol.* 41:2401–2407.
- Peterson, W. L. (1991). *Helicobacter pylori* and peptic ulcer disease. *N. Engl. J. Med.* 324:1043–1048.

- Petersen, A.M. and Krogfelt, K.A. (2003). "Helicobacter pylori: an invading microorganism? A review". *FEMS Immunol. Med. Microbiol.* 36 (3): 117–26.
- Porras, C., Nodora, J. and Sexton, R.(2013). Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). *Cancer Causes Control* .24(2):209–15.
- Pounder, R. E., Ng. D. (1995). The prevalence of Helicobacter pylori infection in different countries. *Aliment Pharmacology and Therapeutics*. 9:33–39.
- Plummer, M. S., Franceschi, J., Vignat, D., Forman, Martel, C., (2015). Global burden of gastric cancer attributable to *Helicobacter pylori*. *International Journal of Cancer*, vol. 136, no. 2, pp. 487–490.
- Queiroz, D. M., Mendes, E. N. and Rocha, G. A. (1987). Indicator medium for isolation of Campylobacter pylori. *J. Clin. Microbiol.* 25:2378–2379.
- Rauws, E. A. J. and Tytgat, G. N. J. (1990). Cure of duodenal ulcer associated with eradication of Helicobacter pylori. *Lancet* 335:1233–1235.
- Rohde, M., Puls, J., Buhrdorf, R., Fischer, W. and Haas, R. (2003). A novel sheated surface organelle of the Helicobacter pylori cag type IV secretion system. *MolMicrobiol.*; 49(1):219–234.
- Roesler, B.M., Costa, S.C.B. and Zeitune, J.M.R. (2011). Virulence factors of Helicobacter pylori and their relationship with the development of early and advanced distal intestinal type gastric adenocarcinoma. In: Tonino P, ed. Gastritis and Gastric Cancer. New Insights in Gastroprotection, Diagnosis and Treatments. Rijeka, Croatia: InTech Publishers.
- Ruiz, B., Correa, P., Fontham, E. T. H and Ramakrishnan, T. (1996). Antral atrophy, Helicobacter pylori colonization, and gastric pH. *Am. J. Clin. Pathol.* 105:96–101.
- Rust, M., Schweinitzer, T. and Josenhans, C. (2008). "Helicobacter Flagella, Motility and Chemotaxis" (<http://www.horizonpress.com/hpl2>). In Yamaoka Y (ed.). Helicobacter pylori: Molecular Genetics and Cellular Biology. Caister Academic Press. ISBN 978-1-904455-31-8.
- Santos, A., Queiroz, D. M., Menard, A., Marais, A., Rocha, G. A., Oliveira, C. A., Nogueira, A. M., Uzeda, M. and Megraud, F. (2003). New pathogenicity marker found in the plasticity region of the Helicobacter pylori genome. *J. Clin. Microbiol.* 41:1651–1655.
- Schmid, E. N., von Recklinghausen, G. and Ansorg, R. (1990). Bacteriophages in Helicobacter (Campylobacter) pylori. *J. Med. Microbiol.* 32:101–104.
- Schreiber, S., Konradt, M., Groll, C., Scheid, P., Hanauer, G., Werling, H.O., Josenhans, C. and Suerbaum, S. (2004). "The spatial orientation of Helicobacter pylori in the gastric mucus" (<https://www.ncbi.nlm.nih.gov/pmc/articles/PM C387367>). *Proc. Natl. Acad. Sci. U.S.A.* 101 (14): 5024–9.

- Secka, O., Antonio, M., Tapgun, M., Berg, D.E., Bottomley, C., Thomas, V., Robert, W., Tumani, C., Julian, E.T., Richard, A.A., (2011). PCR-based genotyping of *Helicobacter pylori* of Gambian children and adults directly from biopsy specimens and bacterial cultures. *Gut Pathogens*; 3:5.
- Sethi, A., Chaudhuri, M., Kelly, L. and Hopman, W. (2013). Prevalence of *Helicobacter pylori* in a First Nations population in northwestern Ontario. *Can Fam Physician*; 59:e182–7.
- Shi, R., Xu, S., Zhang, H., Ding, Y., Sun, G., Huang, X., Chen, X., Li X., Yan, Z., Zhang, G., (2008). Prevalence and risk factors for *Helicobacter pylori* infection in Chinese populations. *Helicobacter*; 13:157-65.
- Sobala, G. M., Crabtree, J. E., Dixon, M. F., Schorah, C. J., Taylor, J. D., Rathbone, B. J., Heatley, R. V. and Axon, A. T. (1991). Acute *Helicobacter pylori* infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. *Gut* 32: 1415–1418.
- 12 Sodhi, J.S., Javid, G. and Zargar, S.A. (2013). Prevalence of *Helicobacter pylori* infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir India. *J. Gastroenterol Hepatol*; 28:808–13.
- Solnick, J. V., Canfield, D. R., Yang, S. and Parsonnet, J. (1999). Rhesus monkey (*Macaca mulatta*) model of *Helicobacter pylori*: noninvasive detection and derivation of specific-pathogen-free monkeys. *Lab. Anim. Sci.* 49:197–201.
- Stark, R.M., Gerwig, G.J., Pitman, R.S., Potts, L.F., Williams, N.A., Greenman, J., Weinzwieg, I.P., Hirst, T.R., Millar, M.R. (1999). "Biofilm formation by *Helicobacter pylori*". *Let Appl Microbiol.* 28 (2): 121–6.
- Suerbaum, S. and M. Achtman. (2004). *Helicobacter pylori*: recombination, population structure and human migrations. *Int. J. Med. Microbiol.* 294: 133–139.
- Suzuki, M., Mimuro, H., Suzuki, T., Park, M., Yamamoto, T. and Sasakawa, C. (2005). Interaction of CagA with Crk plays an important role in *Helicobacter pylori*-induced loss of gastric epithelial cell adhesion. *J Exp Med.*; 202(9):1235–1247.
- Talley, N. J., Zinsmeister, A. R., Weaver, A., DiMagno, E. P., Carpenter, H. A., Perez-Perez, G. And Blaser, M. J. (1991). Gastric adenocarcinoma and *Helicobacter pylori* infection. *J. Natl. Cancer Inst.* 83:1734–1739.
- Thomas, J. E., Gibson, G. R., Darboe, M. K., Dale, A. and Weaver, L. T. (1992). Isolation of *Helicobacter pylori* from human faeces. *Lancet* 340:1194–1195.
- Tsai, C.J., Perry, S., Sanchez, L., Parsonnet, J., (2005). *Helicobacter pylori* infection in different generations of Hispanics in the San Francisco Bay area. *American Journal of Epidemiology* ;162:351-7.
- Tytgat, G. N. (1995). Endoscopic transmission of *Helicobacter pylori*. *Aliment. Pharmacol. Ther.*

- 9(Suppl. 2):105–10. vanBlankenstein M, van Vuuren, A.J., Looman, C.W., Ouwendijk, M., Kuipers, E.J. (2013). The prevalence of *Helicobacter pylori* infection in the Netherlands. *Scand J Gastroenterol*;48:794–800.
- vanDoorn, L.J., Figueiredo, C. and Sanna, R.(1998). Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*. *Gastroenterology*. 115(1):58–66.
- Veenendaal, R. A., Lichtendahl-Bernards, A. T., Pena, A. S., Endtz, H. P., van Boven, C. P. and Lamers, C. B.(1993). Effect of transport medium and transportation time on culture of *Helicobacter pylori* from gastric biopsy specimens. *J. Clin. Pathol*. 46:561–563.
- Veldhuyzen van Zanten, S. O. J., Dixon, M F. and A. Lee. (1999). The gastric transitional zones: neglected links between gastroduodenal pathology and *Helicobacter* ecology. *Gastroenterology* 116:1217–1229.
- Verdu', E., Armstrong, D., Fraser, R., Viani, F., Idstrom, J.-P., Cederberg, C. and Blum, A. L. (1995). Effect of *H.pylori* status on intragastric pH during treatment with omeprazole. *Gut* 36:539–543.
- Vilaichone, R.K., Mahachai, V., Shiota, S., Uchida, T., Ratanachu-ek, T., Tshering, L., Tung, N.L., Fujioka, T., Moriyama, M. and Yamaoka, Y. (2013). Extremely high prevalence of *Helicobacter pylori* infection in Bhutan. *World J Gastroenterol* 19:2806–10.
- Wang, S.H., Zhu, H.F. and He, B.S. (2007). *cagA* + *H. pylori* infection is associated with polarization of T helper cell immune responses in gastric carcinogenesis. *World J Gastroenterol*.; 13(21):2923–2931.
- Yamaoka, Y., Kodama, T., Gutierrez, O., Kim, J.G., Kashima, K. and Graham, D.(1999). Relationship between *Helicobacter pylori* *iceA*, *cagA* and *vacA* status and clinical outcome: studies in four different countries. *J Clin Microbiol*.; 37(7):2274–2279.
- Yamaoka, Y. (2008). Roles of the plasticity regions of *Helicobacter pylori* in gastroduodenal pathogenesis. *J Med Microbial*. 57(5):545–553.
- Yamaoka, Y. (2011). Mechanisms of disease: *Helicobacter pylori* virulence factors. *Nat Rev Gastroenterol Hepatol*.; 7(11):629–641.
- Yan, T.L., Hu, Q.D., Zhang, Q., Li, Y.M., Liang, T.B., (2013). National rates of *Helicobacter pylori* recurrence are significantly and inversely correlated with human development index. *Alimentary Pharmacology & Therapeutics*, vol. 37, no. 10, pp. 963–968.
- Yim, J.Y., Kim, N. and Choi, S.H.(2007). Seroprevalence of *Helicobacter pylori* in South Korea. *Helicobacter*; 12:333–40.
- Yousfi, M. M., Reddy, R. Osato, M. S. and Graham, D. Y. (1996). Culture of *Helicobacter pylori*: effect of preimmersion of biopsy forceps in formalin. *Helicobacter* 1:62–64.

- Yu, Y., Su, L., Wang, X., Wang, X. and Xu, C. (2014). Association between *Helicobacter pylori* infection and pathological changes in the gastric mucosa in Chinese children. *Intern Med*;53:83–8.
- Zhu, Y., Zhou, X., Wu, J., Su, J. and Zhang, G. (2014). Risk factors and prevalence of *Helicobacter pylori* infection in persistent high incidence area of gastric carcinoma in Yangzhong city. *Gastroenterol Res Pract*; 481365.